Hirsutism

1. Clinical Overview

Summary

Hirsutism is the excessive growth of terminal hair in women in a male-pattern distribution, affecting 5-15% of women of reproductive age worldwide. [1] It results from increased androgen production, enhanced androgen sensitivity at the hair follicle level, or both. While often idiopathic or associated with polycystic ovary syndrome (PCOS), hirsutism can signal underlying endocrine disorders requiring investigation. The condition causes significant psychological distress, reduced quality of life, and may indicate associated metabolic abnormalities. [2] Treatment combines cosmetic hair removal methods with medical therapy targeting androgen excess or action, achieving 70-90% improvement in most cases with combination therapy. [3]

Key Facts

• Definition: Excessive terminal hair growth in androgen-sensitive areas in women, quantified by modified Ferriman-Gallwey score ≥8.
• Prevalence: 5-15% of women of reproductive age; varies significantly by ethnicity (20-25% in Mediterranean populations, 2-5% in East Asian populations). [1]
• Pathophysiology: Androgen-dependent hair follicle stimulation via androgen receptors and 5α-reductase conversion to dihydrotestosterone (DHT).
• Commonest Cause: Polycystic ovary syndrome (60-80% of cases); idiopathic hirsutism accounts for 10-20%. [4]
• Scoring: Modified Ferriman-Gallwey score evaluates 9 androgen-sensitive body areas (score ≥8 indicates hirsutism in Caucasian women; ethnic-specific thresholds apply). [5]
• Psychological Impact: Significant distress, anxiety, depression, reduced self-esteem, social withdrawal, and impaired quality of life. [2]
• Associated Conditions: Insulin resistance (50-70% of PCOS cases), metabolic syndrome (33%), infertility (40%), type 2 diabetes (7-10%). [6]
• Treatment Response: Combined oral contraceptives achieve 60-80% improvement; anti-androgens 70-90%; laser therapy 70-90% hair reduction after 4-6 sessions. [3,7]

Clinical Pearls

The Androgen Threshold: Hair growth occurs when serum free testosterone exceeds a threshold (usually > 50 ng/dL or 1.5-2 ng/dL free testosterone), but individual follicular sensitivity varies significantly, explaining why some women with normal androgen levels develop hirsutism.

Ethnic Variations: Mediterranean, Middle Eastern, and South Asian women have higher prevalence (20-25%) and lower Ferriman-Gallwey thresholds (≥6 may indicate hirsutism); East Asian women have lower androgen sensitivity and higher thresholds (≥2-3 may be significant). [5]

Idiopathic Hirsutism: Accounts for 10-20% of cases with normal serum androgen levels but increased 5α-reductase activity in hair follicles and enhanced androgen receptor sensitivity, representing a tissue-level hyperandrogenism. [8]

Progression Over Time: Hirsutism often worsens during reproductive years (peak 20-40 years) due to cumulative androgen exposure and may stabilize or improve post-menopause as ovarian androgen production declines.

Treatment Latency: Medical therapy requires 6-12 months for full effect because hair follicles have 6-month growth cycles (anagen phase); patients must understand this delay to maintain adherence.

Why This Matters Clinically

• Quality of Life Impact: SF-36 scores 15-20 points lower than age-matched controls; significant psychological burden comparable to chronic medical conditions. [2]
• Underlying Pathology: May indicate PCOS (most common), congenital adrenal hyperplasia (CAH), Cushing's syndrome, or androgen-secreting tumors (rare but critical to exclude).
• Metabolic Associations: Strong links to insulin resistance (50-70%), metabolic syndrome (33%), and increased cardiovascular risk (2-3x higher). [6]
• Fertility Implications: Often associated with anovulation (40-60% of PCOS cases) and infertility; investigation may reveal treatable causes.
• Diagnostic Opportunity: Investigation may reveal treatable endocrine disorders; systematic approach prevents missing serious pathology.
• Treatment Efficacy: Combination therapy (OCP + anti-androgen + cosmetic) achieves 70-90% improvement, significantly improving quality of life. [3,7]
• Tumor Detection: Rapid progression, severe virilization, or postmenopausal onset mandates exclusion of androgen-secreting tumors.

---

2. Epidemiology

Global Prevalence

• Overall: 5-15% of women of reproductive age affected globally. [1]
• Age Distribution: Peaks between 18-35 years during peak reproductive years; rare before puberty or after menopause.
• Geographic Variation: Higher prevalence in Mediterranean (20-25%), Middle Eastern (15-20%), and South Asian populations (15-18%).
• Ethnic Differences: Lower in East Asian women (2-5%) due to reduced androgen receptor sensitivity and lower 5α-reductase activity.
• Urban vs Rural: Higher prevalence in urban areas (12-18% vs 8-12% rural) likely due to obesity, sedentary lifestyle, and metabolic factors.

Risk Factors and Odds Ratios

Associated Conditions

• PCOS: 60-80% of hirsutism cases; most common cause in premenopausal women. [4]
• Idiopathic Hirsutism: 10-20% of cases; normal androgen levels, increased follicular sensitivity.
• Congenital Adrenal Hyperplasia (non-classic): 1-8% of cases (varies by ethnicity; higher in Ashkenazi Jewish, Hispanic populations). [12]
• Cushing's Syndrome: less than 1% of cases; important to exclude in severe cases with Cushingoid features.
• Androgen-Secreting Tumors: less than 1% of cases; ovarian (Sertoli-Leydig, granulosa cell) or adrenal tumors.
• Iatrogenic: Anabolic steroids, danazol, testosterone therapy, valproate, cyclosporine, phenytoin.
• Hyperprolactinemia: 5-10% of PCOS cases; can coexist with hirsutism.

Socioeconomic Impact

• Healthcare Utilization: Average 4-6 GP visits/year, 2-3 specialist referrals; significant healthcare costs.
• Work Productivity: 15-25% report work absenteeism due to psychological distress and time for treatments.
• Treatment Costs: Annual expenditure £500-2000/year on cosmetic treatments (waxing, laser, electrolysis).
• Quality of Life: SF-36 scores 15-20 points lower than controls; DLQI (Dermatology Life Quality Index) scores 10-15 (moderate-severe impairment). [2]
• Psychological Costs: 30-40% meet criteria for anxiety disorders; 20-30% for depression; significantly impacts relationships and social functioning. [2]

---

3. Pathophysiology

Step 1: Androgen Production

Ovarian Androgens:

• Thecal cells produce androstenedione and testosterone under luteinizing hormone (LH) stimulation.
• Normal ovarian testosterone production: 50-60% of total circulating testosterone (200-300 µg/day).
• In PCOS: LH excess (LH:FSH ratio > 2:1) drives ovarian hyperandrogenism with 2-3x increased testosterone production. [4]
• Granulosa cell aromatase converts androgens to estrogens; impaired aromatase in PCOS leads to androgen accumulation.

Adrenal Androgens:

• Zona reticularis produces dehydroepiandrosterone (DHEA), DHEA-sulfate (DHEAS), and androstenedione under ACTH stimulation.
• Normal adrenal testosterone contribution: minimal direct testosterone production; DHEA/DHEAS converted peripherally.
• Adrenal hyperandrogenism: 20-30% of PCOS cases have elevated DHEAS (> 700 µg/dL suggests adrenal source). [13]
• Congenital adrenal hyperplasia: 21-hydroxylase deficiency (90% of CAH) shunts steroid precursors to androgen pathway.

Peripheral Conversion:

• Androstenedione converts to testosterone in adipose tissue, liver, and skin via 17β-hydroxysteroid dehydrogenase.
• Obesity increases peripheral conversion: 30-50% higher testosterone production in obese women.
• Adipose tissue aromatase also converts androgens to estrogens (paradoxically protective in some cases).

Step 2: Androgen Transport and Bioavailability

Sex Hormone Binding Globulin (SHBG):

• SHBG binds 60-80% of circulating testosterone with high affinity (Ka ~10^9 M^-1).
• SHBG production by liver is suppressed by insulin and androgens; increased by estrogens and thyroid hormones.
• In PCOS/obesity: insulin resistance and hyperinsulinemia suppress SHBG production by 40-60%, increasing free testosterone. [6]
• SHBG levels less than 20 nmol/L indicate increased bioavailable androgens regardless of total testosterone.

Free and Bioavailable Testosterone:

• Free testosterone: unbound, biologically active fraction (1-3% of total testosterone; normal less than 1.5-2 ng/dL).
• Bioavailable testosterone: free + albumin-bound (30-40% of total; weakly bound, dissociates at tissues).
• Calculated free testosterone using total testosterone, SHBG, albumin is more accurate than direct assays (equilibrium dialysis is gold standard but impractical). [13]

Transport to Target Tissues:

• Free testosterone diffuses into hair follicles, sebaceous glands, and other androgen-sensitive tissues.
• Tissue uptake independent of SHBG; explains why some women with normal total testosterone but low SHBG develop hirsutism.

Step 3: Hair Follicle Response to Androgens

Androgen Receptor Binding:

• Testosterone and DHT bind cytoplasmic androgen receptors in dermal papilla cells.
• Androgen receptor (AR) gene polymorphisms (CAG repeat length) affect receptor sensitivity: shorter repeats = higher sensitivity = greater hirsutism risk. [14]
• Receptor-androgen complex translocates to nucleus, binds androgen response elements (AREs) in DNA.

5α-Reductase Activity:

• Type II 5α-reductase (encoded by SRD5A2 gene) converts testosterone to dihydrotestosterone (DHT) in hair follicles.
• DHT is 2-3x more potent than testosterone at androgen receptors.
• Idiopathic hirsutism: 30-50% higher 5α-reductase activity in skin despite normal serum androgens. [8]
• Genetic polymorphisms in SRD5A2 affect enzyme activity and hirsutism risk.

Gene Expression and Hair Follicle Transformation:

• Androgen-AR complex activates genes promoting hair follicle growth: IGF-1, TGF-β, VEGF.
• Prolongs anagen (growth) phase from weeks to months; vellus hairs transform to terminal hairs.
• Terminal hairs are thicker (> 30 µm diameter), pigmented, and longer (vs vellus hairs less than 30 µm, unpigmented, short).
• Androgen-sensitive areas: upper lip, chin, chest, linea alba, upper back, upper arms, thighs.
• Paradoxically, androgens miniaturize scalp hair follicles (androgenic alopecia) while enlarging body hair follicles.

Step 4: Insulin Resistance and Hyperinsulinemia

Insulin-Androgen Synergy:

• Insulin resistance affects 50-70% of PCOS patients (independent of obesity). [6]
• Hyperinsulinemia stimulates ovarian thecal cells to produce androgens via insulin and IGF-1 receptors.
• Insulin suppresses hepatic SHBG production, increasing free testosterone by 40-60%.
• Insulin enhances LH-stimulated androgen production (synergistic effect).

Mechanisms of Insulin Resistance in PCOS:

• Post-receptor insulin signaling defects: impaired PI3K pathway, normal MAPK pathway (selective insulin resistance).
• Increased serine phosphorylation of insulin receptor substrate-1 (IRS-1) reduces insulin sensitivity.
• Adipocytokine dysregulation: increased leptin, decreased adiponectin impair insulin sensitivity.

Step 5: Associated Endocrine and Metabolic Effects

Ovarian Dysfunction:

• Anovulation in 40-60% of PCOS cases due to arrested follicular development at 5-10 mm stage. [4]
• Irregular menses (oligomenorrhea): cycles > 35 days or less than 9 menses/year.
• Amenorrhea: absence of menses for ≥3 months in 15-20% of severe PCOS cases.
• Unopposed estrogen from anovulation increases endometrial hyperplasia/cancer risk (2-3x).

Metabolic Syndrome:

• Prevalence 33% in PCOS (vs 8-15% in age-matched controls). [6]
• Components: central obesity (waist > 88 cm), hypertension (≥130/85 mmHg), dyslipidemia (triglycerides ≥150 mg/dL, HDL less than 50 mg/dL), impaired fasting glucose (≥100 mg/dL).
• Cardiovascular risk: 2-3x increased risk of coronary artery disease, stroke, venous thromboembolism.

Long-Term Metabolic Risks:

• Type 2 diabetes: 7-10% prevalence in PCOS vs 2-3% in controls; develops 5-10 years earlier. [6]
• Gestational diabetes: 2-3x increased risk (20-30% of PCOS pregnancies).
• Non-alcoholic fatty liver disease (NAFLD): 40-55% prevalence in PCOS.
• Obstructive sleep apnea: 30-40% prevalence in obese PCOS women.

Pathophysiological Variants

Polycystic Ovary Syndrome (60-80% of hirsutism):

• Primary defect: intrinsic ovarian hyperandrogenism (increased CYP17 activity in thecal cells). [4]
• LH excess → thecal cell stimulation → androstenedione/testosterone production.
• Insulin resistance → hyperinsulinemia → ovarian androgen production, reduced SHBG.
• Thecal cell hyperplasia → increased androgen synthesis capacity.
• Genetic factors: familial clustering (50% of first-degree relatives affected), polygenic inheritance.

Idiopathic Hirsutism (10-20% of hirsutism):

• Normal serum total and free testosterone, DHEAS, 17-OHP.
• Normal ovulatory cycles, normal ovarian morphology on ultrasound. [8]
• Increased skin 5α-reductase activity (30-50% higher) → increased local DHT production.
• Enhanced androgen receptor sensitivity in hair follicles (may be due to AR gene polymorphisms).
• Normal SHBG levels distinguish from PCOS.

Non-Classic Congenital Adrenal Hyperplasia (1-8% of hirsutism):

• 21-hydroxylase deficiency (CYP21A2 gene mutations): 90% of CAH cases. [12]
• Partial enzyme deficiency → accumulated 17-hydroxyprogesterone (17-OHP) → shunted to androgen pathway.
• Baseline 17-OHP > 200 ng/dL (6 nmol/L) suggestive; > 1000 ng/dL (30 nmol/L) diagnostic.
• ACTH stimulation test: 17-OHP > 1000 ng/dL at 60 minutes confirms diagnosis.
• Ethnicity variations: higher prevalence in Ashkenazi Jewish (3-5%), Hispanic (1-3%), Mediterranean (1-2%) populations.

Cushing's Syndrome (less than 1% of hirsutism):

• Chronic cortisol excess from pituitary adenoma (Cushing's disease, 70%), adrenal tumor (15%), ectopic ACTH (15%).
• Cortisol has weak androgenic activity; also stimulates adrenal androgen production.
• Clinical features: moon facies, buffalo hump, central obesity, purple striae, proximal myopathy, hypertension.
• Screening: 24-hour urinary free cortisol (UFC), late-night salivary cortisol, 1 mg overnight dexamethasone suppression test.

Androgen-Secreting Tumors (less than 1% of hirsutism):

• Ovarian tumors: Sertoli-Leydig cell tumor, granulosa-theca cell tumor, lipoid cell tumor.
• Adrenal tumors: adrenal adenoma, adrenal carcinoma (rare but aggressive).
• Clinical clues: rapid progression (less than 6 months), severe virilization (clitoromegaly > 1 cm, voice deepening, breast atrophy), postmenopausal onset.
• Biochemical clues: testosterone > 150-200 ng/dL (5-7 nmol/L), DHEAS > 700 µg/dL (19 µmol/L).
• Imaging: pelvic ultrasound/MRI for ovarian masses, adrenal CT/MRI for adrenal masses.

---

4. Clinical Presentation

Distribution Patterns of Terminal Hair Growth

• Facial (most distressing): Upper lip (mustache pattern), chin (beard pattern), sideburns, jawline, neck.
• Trunk: Areolar (periareolar hair), chest (intermammary, presternal), upper back (interscapular), linea alba (midline abdomen).
• Abdomen: Upper abdomen (epigastric), lower abdomen (suprapubic extending above pubis).
• Extremities: Upper arms (shoulders, upper anterior/posterior arms), inner thighs, lower legs.
• Less Common: Lower back (lumbosacral), buttocks, perianal (rare, suggests severe hyperandrogenism).

Modified Ferriman-Gallwey Scoring System

The modified Ferriman-Gallwey (mFG) score quantifies hirsutism severity by grading terminal hair growth in 9 androgen-sensitive body areas on a 0-4 scale (maximum score 36). [5]

Scoring Criteria for Each Area (0-4):

Total Score Interpretation:

Ethnic-Specific Thresholds: [5]

• Caucasian (European): ≥8 indicates hirsutism
• Mediterranean/Middle Eastern: ≥6-7 may be significant (higher baseline)
• Hispanic/Latino: ≥6-7 may be significant
• East Asian: ≥2-3 may be significant (much lower baseline)
• African American: ≥8-9 (variable, consider individual baseline)

Limitations of Ferriman-Gallwey Score:

• Does not account for prior cosmetic treatments (waxing, laser, shaving) which may underestimate true severity.
• Observer variability: inter-rater reliability moderate (κ = 0.6-0.7).
• Does not correlate perfectly with serum androgen levels (some high-scorers have normal androgens; some low-scorers have elevated androgens).
• Ethnic variations require adjusted thresholds.

Associated Clinical Features by Underlying Cause

Polycystic Ovary Syndrome (PCOS):

• Menstrual irregularity: Oligomenorrhea (cycles > 35 days) or amenorrhea (> 3 months without menses) in 70-80%. [4]
• Acne: Inflammatory acne affecting face, chest, back in 50-70% of cases (often persistent adult acne).
• Seborrhea: Oily skin, scalp seborrheic dermatitis.
• Androgenic alopecia: Male-pattern baldness (frontal-temporal recession, vertex thinning) in 20-40%.
• Obesity: BMI ≥30 in 40-60% of PCOS cases (but 30-40% are normal weight).
• Acanthosis nigricans: Velvety hyperpigmented skin in intertriginous areas (neck, axillae, groin) indicating insulin resistance; present in 20-40%.
• Skin tags: Multiple small skin tags (acrochordons) associated with insulin resistance.
• Infertility: Anovulatory infertility in 40-60%; may present as primary complaint.

Congenital Adrenal Hyperplasia (Non-Classic CAH):

• Post-pubertal onset: Symptoms typically begin in adolescence or early adulthood (vs classic CAH presenting in infancy). [12]
• Mild virilization: Hirsutism, acne, but typically no clitoromegaly or severe virilization.
• Normal or mildly irregular menses: 40-50% have normal ovulatory cycles (unlike PCOS).
• Family history: May have relatives with CAH, infertility, or ambiguous genitalia (classic CAH).
• Short stature: Advanced bone age in childhood may result in shorter final adult height (if undiagnosed/untreated).
• Early pubarche: Premature development of pubic/axillary hair before age 8 (retrospectively).

Cushing's Syndrome:

• Moon facies: Rounded, plethoric facial appearance with facial plethora.
• Central obesity: Truncal fat accumulation with relatively thin extremities; buffalo hump (dorsocervical fat pad); supraclavicular fullness.
• Skin changes: Purple striae (> 1 cm wide) on abdomen, thighs, breasts; easy bruising; thin, fragile skin; poor wound healing.
• Proximal myopathy: Difficulty rising from chair, climbing stairs; proximal muscle weakness and wasting.
• Hypertension: Present in 80-90% of cases; often difficult to control.
• Glucose intolerance: Impaired fasting glucose or overt diabetes in 40-60%.
• Osteoporosis: Fractures, vertebral compression, low bone density on DEXA.
• Psychiatric symptoms: Depression (50-70%), anxiety, emotional lability, cognitive impairment.

Androgen-Secreting Tumors (Ovarian or Adrenal):

• Rapid progression: Onset over weeks to months (vs years in PCOS). [15]
• Severe virilization: Clitoromegaly (clitoral length > 1 cm), deepening voice (irreversible laryngeal changes), breast atrophy, increased muscle mass, male-pattern baldness.
• Oligomenorrhea/amenorrhea: Severe androgen excess suppresses ovulation rapidly.
• Abdominal/pelvic mass: Palpable mass on examination (if tumor > 5 cm).
• Rapid weight loss: Adrenal carcinoma may present with cachexia, pain, malaise.
• Age: Postmenopausal onset of hirsutism highly suspicious for tumor (ovarian androgen production should decline after menopause).

Red Flags for Serious Pathology (Require Urgent Investigation)

1. Rapid Progression: Symptom onset over less than 6 months suggests androgen-secreting tumor rather than PCOS (which develops over years). [15]
2. Severe Virilization: Deepening voice (laryngeal cartilage growth is irreversible), clitoromegaly (clitoral length > 1 cm, width > 0.5 cm), increased muscle mass, male-pattern baldness, breast atrophy.
3. Postmenopausal Onset: New hirsutism after menopause is ovarian or adrenal tumor until proven otherwise (normal postmenopausal ovaries produce minimal androgens).
4. Cushingoid Features: Moon facies, buffalo hump, purple striae > 1 cm wide, proximal myopathy, hypertension, easy bruising.
5. Very High Testosterone: Serum total testosterone > 150-200 ng/dL (> 5-7 nmol/L) suggests androgen-secreting tumor. [13]
6. Very High DHEAS: Serum DHEAS > 700 µg/dL (> 19 µmol/L) suggests adrenal tumor (vs PCOS typically DHEAS 200-400 µg/dL). [13]
7. Abdominal/Pelvic Mass: Palpable mass on examination or imaging suggests ovarian or adrenal neoplasm.
8. Severe Acne + Alopecia: Combination of severe cystic acne and rapid-onset androgenic alopecia suggests very high androgen levels.
9. Prepubertal Onset: Virilization before age 8 suggests adrenal tumor, CAH, or exogenous androgen exposure.

---

5. Clinical Examination

General Assessment

• Height and Weight: Calculate BMI (obesity associated with PCOS and insulin resistance).
• Blood Pressure: Hypertension suggests Cushing's syndrome, metabolic syndrome, or chronic kidney disease.
• Overall Appearance: Assess for Cushingoid features, virilization, acne distribution, alopecia pattern.

Skin Examination

• Hirsutism Scoring: Systematically score each of the 9 Ferriman-Gallwey areas (upper lip, chin, chest, upper back, lower back, upper abdomen, lower abdomen, upper arms, thighs).
• Acne: Assess face, chest, back for inflammatory acne (papules, pustules, nodules, cysts); grade severity.
• Seborrhea: Oily skin, scalp seborrheic dermatitis.
• Acanthosis nigricans: Velvety hyperpigmented plaques in neck (posterior/lateral), axillae, groin, inframammary regions (marker of insulin resistance).
• Striae: Purple/red striae > 1 cm wide suggest Cushing's syndrome (vs normal striae from weight gain/pregnancy which are white/silver and less than 1 cm).
• Bruising: Easy bruising, thin fragile skin suggest Cushing's syndrome or corticosteroid use.
• Skin tags: Multiple acrochordons associated with insulin resistance and PCOS.

Hair Examination

• Androgenic Alopecia: Assess Ludwig pattern (diffuse thinning over crown and vertex) or male-pattern (frontal-temporal recession, M-shaped hairline).
• Terminal vs Vellus Hair: Terminal hairs are thick (> 30 µm), pigmented, long; vellus hairs are thin (less than 30 µm), unpigmented, short (less than 1 cm).
• Distribution: Note areas of terminal hair growth (especially facial, chest, abdomen).

Endocrine Examination

• Thyroid: Palpate for goiter, nodules (thyroid disorders can affect SHBG levels; hyperthyroidism increases SHBG).
• Breasts: Assess for galactorrhea (suggests hyperprolactinemia), gynaecomastia (rare in women but can occur with extreme androgen excess).
• Pelvic Examination: Assess for clitoromegaly (normal clitoral length less than 1 cm, width less than 0.5 cm); clitoromegaly suggests severe virilization. Palpate for adnexal masses (ovarian tumors).

Cushingoid Features

• Moon Facies: Rounded face with loss of normal contours, facial plethora, facial fullness.
• Central Obesity: Truncal fat accumulation with thin limbs; measure waist circumference (> 88 cm in women indicates central obesity).
• Buffalo Hump: Dorsocervical fat pad (between C7-T1 vertebrae).
• Supraclavicular Fullness: Fat pads above clavicles.
• Proximal Myopathy: Test hip flexion (difficulty rising from squat), shoulder abduction strength; proximal muscle wasting.

Abdominal Examination

• Palpable Masses: Large ovarian tumors (> 5 cm) or adrenal tumors (> 8-10 cm) may be palpable.
• Hepatomegaly: Non-alcoholic fatty liver disease common in PCOS; assess liver size.
• Striae: Purple striae > 1 cm wide on abdomen, flanks, breasts suggest Cushing's syndrome.

---

6. Investigations

Essential First-Line Investigations

1. Androgen Testing Panel [13]

Collect fasting morning sample (8-10 AM) to account for diurnal variation; avoid mid-cycle surges:

Interpretation Algorithm for Androgen Panel:

• Normal androgens + hirsutism: Idiopathic hirsutism (increased skin 5α-reductase activity).
• Mildly elevated testosterone (50-150 ng/dL), low SHBG: PCOS (most common).
• Testosterone 50-150 ng/dL, elevated 17-OHP (> 200 ng/dL): Non-classic CAH (confirm with ACTH stimulation).
• Testosterone > 150-200 ng/dL: Androgen-secreting ovarian tumor (urgent pelvic imaging).
• DHEAS > 700 µg/dL: Adrenal tumor (urgent adrenal CT).
• Elevated androgens + Cushingoid features: Cushing's syndrome (screen with 24-hr UFC, late-night salivary cortisol, DST).

2. Ovarian Assessment

Pelvic Ultrasound (Transvaginal Preferred):

• PCOS Morphology (Rotterdam Criteria): [4]
  • "Polycystic ovaries: ≥12 follicles measuring 2-9 mm in diameter per ovary, and/or"
  • "Increased ovarian volume: > 10 mL per ovary (calculated as length × width × height × 0.5)"
  • "Note: Polycystic ovaries on ultrasound occur in 20-30% of normal women without PCOS; diagnosis requires 2 of 3 Rotterdam criteria (see below)"
• Ovarian Tumors: Solid or complex cystic masses; any ovarian mass with solid component requires further evaluation (MRI, tumor markers, surgical consultation).
• Timing: Perform in early follicular phase (days 3-5) to avoid luteal cysts mimicking polycystic appearance.

Anti-Müllerian Hormone (AMH):

• PCOS: AMH > 35-40 pmol/L (> 5-6 ng/mL) supports PCOS diagnosis (reflects increased antral follicle count). [16]
• Correlation: AMH correlates with ovarian follicle count and PCOS severity.
• Advantage: AMH does not vary significantly throughout cycle; can be measured any time.

LH/FSH Ratio:

• PCOS: LH:FSH ratio > 2-3:1 suggests PCOS (present in 40-50% of PCOS cases, not required for diagnosis). [4]
• Mechanism: Increased LH pulse frequency in PCOS drives ovarian androgen production.
• Timing: Measure in early follicular phase (days 3-5).

3. Metabolic Screening [6]

PCOS is associated with metabolic syndrome in 33% of cases; screen all hirsute women:

Oral Glucose Tolerance Test (OGTT):

• Indications: BMI ≥25, family history of diabetes, history of gestational diabetes, metabolic syndrome features.
• Protocol: Fasting glucose, then 75g oral glucose load, measure glucose at 120 minutes.
• Interpretation: 2-hour glucose less than 140 mg/dL (normal), 140-199 mg/dL (impaired glucose tolerance), ≥200 mg/dL (diabetes).
• PCOS: 30-40% have IGT; 7-10% have diabetes; perform OGTT even if fasting glucose normal.

4. Thyroid and Prolactin Screening

Hyperprolactinemia Workup:

• Repeat prolactin (stress, recent breast examination, medications can elevate transiently).
• If confirmed elevated, check macroprolactin (rule out assay interference).
• MRI pituitary if prolactin > 50 ng/mL or symptoms of pituitary tumor (headaches, visual field defects).

---

Advanced/Second-Line Investigations

1. ACTH Stimulation Test for CAH [12]

Indications:

• Baseline 17-OHP > 200 ng/dL (> 6 nmol/L) in follicular phase.
• Clinical suspicion for CAH (early pubarche, family history, ethnicity, refractory hirsutism).

Protocol:

• Baseline 17-OHP (8 AM, follicular phase days 3-5).
• Administer synthetic ACTH (cosyntropin) 250 µg IV or IM.
• Measure 17-OHP at 0, 30, and 60 minutes post-ACTH.

Interpretation:

• Normal: 17-OHP at 60 min less than 1000 ng/dL (less than 30 nmol/L) excludes CAH.
• Non-Classic CAH: 17-OHP at 60 min ≥1000 ng/dL (≥30 nmol/L) confirms diagnosis.
• Equivocal: 17-OHP 500-1000 ng/dL may represent heterozygote carrier or mild CAH; genetic testing recommended.

Genetic Testing for CAH:

• CYP21A2 gene sequencing if ACTH stimulation test equivocal or family planning.
• Identifies heterozygote carriers (important for reproductive counseling).

2. Cushing's Syndrome Screening (if clinically suspected)

First-Line Screening Tests (perform ≥2):

1. 24-Hour Urinary Free Cortisol (UFC): Collect 24-hour urine; > 2-3x upper limit of normal (> 150-200 µg/24hr) suggests Cushing's.
2. Late-Night Salivary Cortisol: Collect saliva at 11 PM (nadir in normal diurnal rhythm); elevated late-night cortisol (> 145 ng/dL) suggests Cushing's.
3. 1 mg Overnight Dexamethasone Suppression Test (DST): Give 1 mg dexamethasone orally at 11 PM; measure cortisol at 8 AM next day; cortisol less than 1.8 µg/dL excludes Cushing's; > 5 µg/dL strongly suggests Cushing's; 1.8-5 µg/dL is equivocal.

Second-Line Testing (if screening positive):

• Low-dose dexamethasone suppression test (LDDST): 0.5 mg dexamethasone every 6 hours for 48 hours.
• High-dose dexamethasone suppression test (HDDST): differentiate pituitary (Cushing's disease) from adrenal or ectopic ACTH.
• MRI pituitary, CT adrenal, CRH stimulation test as directed by endocrinologist.

3. Imaging for Androgen-Secreting Tumors [15]

Ovarian Imaging:

• Indications: Testosterone > 150-200 ng/dL, rapid virilization, palpable adnexal mass, postmenopausal hirsutism.
• First-Line: Transvaginal ultrasound (detects masses > 1-2 cm, characterizes solid vs cystic).
• Second-Line: Pelvic MRI with contrast (better tissue characterization, detects masses less than 1 cm, distinguishes benign from malignant features).
• Tumor Markers: If ovarian mass detected, check CA-125 (elevated in epithelial ovarian cancer), inhibin (elevated in granulosa cell tumors), testosterone (very high in Sertoli-Leydig tumors).

Adrenal Imaging:

• Indications: DHEAS > 700 µg/dL, rapid virilization, Cushingoid features, abdominal mass.
• First-Line: CT adrenal with thin slices (1-3 mm) pre- and post-contrast.
  • "Adenoma: less than 4 cm, homogeneous, less than 10 Hounsfield units (HU) on non-contrast CT (lipid-rich), rapid contrast washout > 50% at 10 min."
  • "Adrenal carcinoma: > 4-6 cm, heterogeneous, > 10 HU (lipid-poor), irregular margins, necrosis, local invasion, slow washout less than 50% at 10 min."
• Second-Line: MRI adrenal (if CT inconclusive; chemical shift imaging distinguishes adenoma from carcinoma).
• PET-CT: If adrenal carcinoma suspected (staging, metastases).

4. Ovarian/Adrenal Vein Sampling (rarely needed)

Indications:

• Severe hyperandrogenism with negative imaging (no mass identified on CT/MRI).
• Biochemical evidence of tumor (testosterone > 200 ng/dL) but no identifiable source.

Protocol:

• Catheterize ovarian veins and adrenal veins; measure testosterone and DHEAS from each vein.
• Compare lateralization: > 2-3x difference suggests unilateral source.
• Technically challenging; high failure rate; rarely performed (reserved for surgical planning when tumor suspected but not localized).

---

Diagnostic Algorithm: Differentiating Ovarian vs Adrenal Hyperandrogenism

WOMAN WITH HIRSUTISM
        ↓
┌───────────────────────────────────────────────┐
│    COMPREHENSIVE ANDROGEN PANEL               │
│  - Total & Free Testosterone                  │
│  - DHEAS                                      │
│  - 17-OHP (follicular phase)                  │
│  - SHBG                                       │
└───────────────────────────────────────────────┘
        ↓
    ┌───────────┴─────────────┐
    ↓                         ↓
NORMAL ANDROGENS         ELEVATED ANDROGENS
    ↓                         ↓
Idiopathic Hirsutism      ┌────┴─────────┐
(10-20% of cases)         ↓              ↓
- Normal ovulatory    MILD ELEVATION  SEVERE ELEVATION
  cycles              (T less than 150 ng/dL)  (T > 150-200 ng/dL)
- Normal ovaries          ↓              ↓
- Increased skin      ┌────┴────┐    URGENT IMAGING
  5α-reductase        ↓         ↓    (Tumor Suspected)
- Rx: Anti-androgens  PCOS     CAH       ↓
  + cosmetic          ↓         ↓    ┌────┴─────┐
                      |         |    ↓          ↓
                      |    17-OHP > 200? DHEAS > 700?
                      |         ↓              ↓
                      |    ACTH Stim Test  Adrenal CT
                      |         ↓              ↓
                      |    Non-Classic CAH  Adrenal Tumor
                      |    (1-8% of cases)  (less than 1% of cases)
                      |                     
                  LH:FSH > 2:1?          ↓
                  AMH > 35 pmol/L?   Ovarian Imaging
                  Polycystic ovaries?   (Ultrasound/MRI)
                      ↓                  ↓
                  PCOS Diagnosis     Ovarian Tumor
                  (60-80% of cases)  (less than 1% of cases)

Key Differentiating Features:

---

PCOS Diagnostic Criteria Comparison

Three major diagnostic criteria exist for PCOS; Rotterdam criteria (2003) are most widely used: [4]

1. Rotterdam Criteria (2003) - Most Widely Used Diagnosis requires 2 of 3:

1. Oligo/anovulation: less than 9 menses/year or cycles > 35 days.
2. Clinical or biochemical hyperandrogenism:
   • Clinical: Hirsutism (mFG score ≥8), acne, androgenic alopecia.
   • Biochemical: Elevated testosterone, free testosterone, or androstenedione.
3. Polycystic ovaries on ultrasound: ≥12 follicles (2-9 mm) per ovary and/or ovarian volume > 10 mL.

Exclusion criteria: Must exclude other causes (CAH, Cushing's syndrome, androgen-secreting tumors, hyperprolactinemia, thyroid disorders).

Phenotypes:

• Phenotype A (Classic PCOS): All 3 criteria (hyperandrogenism + ovulatory dysfunction + polycystic ovaries) - most severe, highest metabolic risk.
• Phenotype B: Hyperandrogenism + ovulatory dysfunction (no polycystic ovaries).
• Phenotype C: Hyperandrogenism + polycystic ovaries (ovulatory).
• Phenotype D (Mild PCOS): Ovulatory dysfunction + polycystic ovaries (no hyperandrogenism) - mildest phenotype, controversial inclusion.

2. Androgen Excess Society (AES) Criteria (2006) Diagnosis requires:

1. Hyperandrogenism (clinical or biochemical) - REQUIRED.
2. Ovarian dysfunction (oligo/anovulation or polycystic ovaries).

Difference from Rotterdam: Hyperandrogenism is mandatory; excludes Phenotype D (ovulatory dysfunction + polycystic ovaries without hyperandrogenism).

3. NIH Criteria (1990) - Original, Most Restrictive Diagnosis requires BOTH:

1. Oligo/anovulation - REQUIRED.
2. Clinical or biochemical hyperandrogenism - REQUIRED.

Difference from Rotterdam: Does not consider ovarian morphology; most restrictive; identifies only classic PCOS (Phenotypes A and B).

Summary Table:

Clinical Implication: Rotterdam criteria identify more women with PCOS (including milder phenotypes); useful for early detection and metabolic risk screening. AES criteria focus on hyperandrogenism as core feature. NIH criteria identify classic severe PCOS.

---

7. Management

Management Algorithm

HIRSUTISM DIAGNOSED (mFG score ≥8)
        ↓
┌──────────────────────────────────────────────┐
│    IDENTIFY AND TREAT UNDERLYING CAUSE      │
│  - PCOS: Lifestyle + OCP ± metformin        │
│  - CAH: Glucocorticoid replacement          │
│  - Tumor: Surgical resection (urgent)       │
│  - Cushing's: Treat underlying cause        │
│  - Iatrogenic: Stop offending medication    │
└──────────────────────────────────────────────┘
        ↓
┌──────────────────────────────────────────────┐
│    ASSESS FERTILITY DESIRE                   │
└──────────────────────────────────────────────┘
    ┌───────────┴─────────────┐
    ↓                         ↓
NOT SEEKING PREGNANCY     SEEKING PREGNANCY
    ↓                         ↓
MEDICAL THERAPY          FERTILITY TREATMENT
    ↓                         ↓
┌────────────────┐      - Lifestyle modification
│ First-Line:    │      - Weight loss (if BMI ≥25)
│ Combined OCP   │      - Metformin (if insulin resistant)
│ (ethinylestradiol│      - Clomiphene citrate (ovulation induction)
│ + cyproterone   │      - Letrozole (alternative to clomiphene)
│ or drospirenone)│      - Gonadotropins (if clomiphene fails)
└────────────────┘      - IVF (if other methods fail)
    ↓                         ↓
After 6-12 months       Continue until pregnancy achieved
If inadequate response      ↓
    ↓                   AFTER PREGNANCY:
┌────────────────┐      Resume medical therapy for hirsutism
│ Add Anti-Androgen│      (avoid anti-androgens while breastfeeding)
│ - Spironolactone│
│   50-200 mg/day │
│ - Finasteride   │
│   2.5-5 mg/day  │
│ - Flutamide     │
│   250 mg bid    │
└────────────────┘
    ↓
┌──────────────────────────────────────────────┐
│    ADD COSMETIC TREATMENTS                   │
│  - Laser hair removal (alexandrite/ND:YAG)  │
│  - Electrolysis (permanent)                  │
│  - Eflornithine 13.9% cream (adjunct)        │
│  - Temporary: Waxing, shaving, threading    │
└──────────────────────────────────────────────┘
    ↓
┌──────────────────────────────────────────────┐
│    MONITORING & LONG-TERM MANAGEMENT         │
│  - Treatment response (mFG score q6-12mo)   │
│  - Side effects (electrolytes, LFTs)        │
│  - Metabolic screening (OGTT, lipids q1-2y) │
│  - Psychological support (anxiety, QoL)     │
│  - Transition to maintenance therapy         │
└──────────────────────────────────────────────┘

---

Pharmacological Treatment

1. Combined Oral Contraceptives (First-Line for Non-Pregnant Women) [3,7]

Mechanism of Action:

• Suppress LH and FSH → reduce ovarian androgen production (↓ testosterone by 40-60%).
• Estrogen stimulates hepatic SHBG production → reduce free testosterone (↑ SHBG by 2-4x).
• Progestins with anti-androgenic activity (cyproterone, drospirenone) competitively block androgen receptors.
• Regulate menstrual cycles, provide endometrial protection (reduce endometrial cancer risk from unopposed estrogen).

Preferred Formulations for Hirsutism:

Efficacy:

• 60-80% improvement in hirsutism after 6-12 months. [3]
• Ferriman-Gallwey score reduction: 15-30% from baseline.
• Response time: 3-6 months for clinical effect (due to hair growth cycle latency).
• Maximal effect: 9-12 months; may continue improving up to 24 months.

Dosing:

• Standard regimen: 21 days active pills, 7 days placebo (withdrawal bleed).
• Continuous regimen: Back-to-back packs without placebo week (may reduce androgen rebound during placebo week; improves cycle control).

Contraindications:

• History of venous thromboembolism (VTE), pulmonary embolism, stroke.
• Active liver disease, hepatic adenoma.
• Breast cancer or other hormone-sensitive malignancy.
• Uncontrolled hypertension (≥160/100 mmHg).
• Migraine with aura (increased stroke risk).
• Age > 35 years + smoking ≥15 cigarettes/day (cardiovascular risk).
• BMI > 40 (higher VTE risk; consider lower-dose estrogen or progestin-only options).

Side Effects:

• Breakthrough bleeding (10-20%, especially first 3 months).
• Nausea, breast tenderness, headaches (5-15%).
• Mood changes (5-10%; monitor for depression/anxiety).
• Weight gain (variable, often fluid retention; 1-2 kg on average).
• VTE risk: Baseline 1-2/10,000 women-years → 6-12/10,000 with COC (varies by progestin; desogestrel/drospirenone higher risk than levonorgestrel).

Monitoring:

• Baseline: Blood pressure, BMI, family history of VTE/breast cancer.
• Follow-up: BP at 3 months, then annually; assess side effects, adherence.
• Long-term: No routine laboratory monitoring unless specific concerns (e.g., migraine onset, leg pain).

---

2. Anti-Androgens (Second-Line or Add-On Therapy) [3,7,17]

Always prescribe with effective contraception (all anti-androgens are teratogenic and can feminize male fetuses).

A. Spironolactone (Aldosterone Antagonist + Anti-Androgen)

Mechanism:

• Competitive antagonist of androgen receptor (blocks testosterone and DHT binding).
• Inhibits 5α-reductase (reduces DHT production).
• Inhibits androgen biosynthesis (reduces ovarian/adrenal androgen production).
• Weak anti-mineralocorticoid effect (diuretic, potassium-sparing).

Dosing:

• Start: 50 mg once or twice daily (50-100 mg/day).
• Maintenance: 100-200 mg/day in 1-2 divided doses.
• Maximum: 200 mg/day (higher doses no additional benefit, increased side effects).

Efficacy:

• 70-90% improvement after 6-12 months. [17]
• Ferriman-Gallwey score reduction: 30-50% from baseline.
• Superior to finasteride for hirsutism; comparable to cyproterone acetate.

Side Effects:

• Menstrual irregularity (40-50%): Breakthrough bleeding, polymenorrhea (reason to combine with OCP).
• Hyperkalemia (5-10%): Risk higher in renal impairment, diabetes, ACE inhibitor use.
• Orthostatic hypotension, dizziness (5-10%).
• Breast tenderness, mastodynia (10-15%).
• Fatigue (5-10%).
• Rare: Gynecomastia in males (if inadvertently prescribed), hepatotoxicity.

Contraindications:

• Renal impairment (eGFR less than 30 mL/min).
• Hyperkalemia (K > 5.0 mEq/L).
• Addison's disease (risk of hyperkalemia).
• Pregnancy (teratogenic; feminization of male fetus).

Monitoring:

• Baseline: Serum potassium, creatinine, blood pressure.
• Follow-up: Potassium and creatinine at 1 month, then every 6-12 months.
• Avoid potassium supplements, potassium-sparing diuretics, ACE inhibitors/ARBs (additive hyperkalemia risk).

---

B. Finasteride (5α-Reductase Inhibitor)

Mechanism:

• Selective inhibitor of type II 5α-reductase (blocks conversion of testosterone → DHT in hair follicles).
• Reduces DHT levels by 60-70% in scalp and skin.

Dosing:

• 2.5-5 mg once daily (2.5 mg may be sufficient for hirsutism; 5 mg FDA-approved for androgenic alopecia in men).

Efficacy:

• 60-70% improvement after 6-12 months. [18]
• Less effective than spironolactone or cyproterone for hirsutism but effective for androgenic alopecia.
• Ferriman-Gallwey score reduction: 20-40% from baseline.

Side Effects:

• Menstrual irregularity (10-20%).
• Decreased libido (5-10% in men; less studied in women).
• Breast tenderness (5%).
• Depression, mood changes (rare but reported).
• Hepatotoxicity (rare; monitor LFTs).

Contraindications:

• Pregnancy (Category X: severe teratogenicity, genital abnormalities in male fetuses).
• Must use effective contraception.

Monitoring:

• Baseline: Pregnancy test, liver function tests.
• Follow-up: LFTs at 3-6 months, then as clinically indicated.
• Effective contraception mandatory (finasteride remains in system for weeks; stop 3-6 months before planned pregnancy).

---

C. Cyproterone Acetate (Progestogenic Anti-Androgen)

Mechanism:

• Potent competitive antagonist of androgen receptor.
• Progestogenic activity (suppresses LH/FSH → reduces ovarian androgen production).
• Weak glucocorticoid activity.

Dosing:

• Low-dose: 2 mg combined with ethinylestradiol 35 µg in OCP (co-cyprindiol; Dianette).
• High-dose (rarely used): 25-50 mg/day on days 1-15 of cycle + OCP (reserved for severe hirsutism refractory to standard therapy).

Efficacy:

• 70-90% improvement with co-cyprindiol (2 mg) after 6-12 months. [3]
• High-dose (25-50 mg): 80-95% improvement but higher side effect burden.
• Ferriman-Gallwey score reduction: 40-60% from baseline.

Side Effects:

• Fatigue, lethargy (20-30% with high-dose).
• Weight gain (10-20%).
• Decreased libido (10-20%).
• Mood changes, depression (10-15%).
• Hepatotoxicity (rare but serious; monitor LFTs; contraindicated in liver disease).
• Meningioma risk (dose-dependent; very rare with low-dose 2 mg but reported with cumulative high-dose > 60 g lifetime).
• VTE risk (higher than other OCPs due to progestogenic + estrogenic activity).

Contraindications:

• Pregnancy (teratogenic).
• Liver disease (hepatotoxicity risk).
• History of meningioma.
• Severe depression.
• VTE history.

Monitoring:

• Baseline: LFTs, pregnancy test.
• Follow-up: LFTs every 6 months (especially high-dose); monitor mood, weight.

Availability:

• Europe: Widely available (co-cyprindiol is first-line OCP for hirsutism).
• USA: Not FDA-approved as OCP; available as stand-alone cyproterone for severe hirsutism (off-label).

---

D. Flutamide (Pure Non-Steroidal Anti-Androgen)

Mechanism:

• Selective competitive antagonist of androgen receptor (no hormonal activity).

Dosing:

• 250 mg once or twice daily (250-500 mg/day).
• Lower doses (125 mg/day) may be effective with fewer side effects.

Efficacy:

• 70-85% improvement after 6-12 months.
• Similar efficacy to spironolactone and cyproterone. [19]

Side Effects:

• Hepatotoxicity (most concerning): Severe liver injury in 0.1-0.5% (rare but potentially fatal); requires close LFT monitoring.
• Dry skin, decreased libido (10-15%).
• Gastrointestinal upset (10%).

Contraindications:

• Liver disease.
• Pregnancy (teratogenic).

Monitoring:

• Baseline: LFTs (ALT, AST, bilirubin).
• Follow-up: LFTs monthly for first 4 months, then every 3 months (hepatotoxicity risk).
• Discontinue if ALT > 2-3x upper limit of normal.

Usage:

• Second-line or third-line (due to hepatotoxicity risk).
• Reserved for severe hirsutism refractory to spironolactone/cyproterone.
• Less commonly used due to safety concerns.

---

Comparative Efficacy of Anti-Androgens:

Clinical Recommendation: Spironolactone 100-200 mg/day + combined OCP (ethinylestradiol + cyproterone or drospirenone) is first-line combination therapy for hirsutism in women not seeking pregnancy. [3,7]

---

3. Insulin Sensitizers (for PCOS with Insulin Resistance) [6,20]

A. Metformin

Mechanism:

• Improves insulin sensitivity → reduces hyperinsulinemia → reduces ovarian androgen production.
• Suppresses hepatic gluconeogenesis → lowers fasting glucose.
• Does NOT directly affect androgen receptors or 5α-reductase.

Dosing:

• Start: 500 mg once daily with food (reduce GI side effects).
• Titrate: Increase by 500 mg weekly to target dose.
• Maintenance: 1500-2000 mg/day in 2-3 divided doses (e.g., 850 mg twice daily or 500 mg three times daily).
• Extended-release (XR) formulation: 1500-2000 mg once daily (better GI tolerability).

Efficacy for Hirsutism:

• Modest effect: 30-50% improvement after 6-12 months (less effective than OCP or anti-androgens). [20]
• Ferriman-Gallwey score reduction: 10-20% from baseline.
• Main benefit: Improves ovulatory function (50-60% resume ovulation), weight loss (2-5 kg), metabolic parameters (insulin, glucose, lipids).
• Best as adjunct to OCP/anti-androgens for PCOS with insulin resistance.

Indications:

• PCOS with insulin resistance (HOMA-IR > 2.5, fasting insulin > 15 µIU/mL).
• BMI ≥25 (obesity/overweight).
• Prediabetes or impaired glucose tolerance.
• Fertility enhancement (ovulation induction).

Side Effects:

• Gastrointestinal (50-70%): Nausea, diarrhea, abdominal discomfort (usually transient, improve after 2-4 weeks; reduce by slow titration, take with food).
• Vitamin B12 deficiency (5-10% with long-term use > 2-3 years): Monitor B12 annually, supplement if less than 200 pg/mL.
• Lactic acidosis (extremely rare: less than 1/100,000; risk higher in renal impairment, liver disease, sepsis, heart failure).

Contraindications:

• eGFR less than 30 mL/min (avoid); eGFR 30-45 mL/min (use with caution, reduce dose).
• Severe liver disease (increased lactic acidosis risk).
• Acute illness (sepsis, MI, respiratory failure, dehydration).
• Alcohol abuse (increased lactic acidosis risk).

Monitoring:

• Baseline: Creatinine/eGFR, LFTs, vitamin B12.
• Follow-up: Creatinine/eGFR annually; vitamin B12 every 1-2 years.

---

B. Thiazolidinediones (Pioglitazone, Rosiglitazone)

Mechanism:

• PPARγ agonists → improve insulin sensitivity in adipose tissue, muscle, liver.
• Reduce ovarian androgen production.

Dosing:

• Pioglitazone: 15-45 mg once daily.
• Rosiglitazone: 4-8 mg once daily (less commonly used due to cardiovascular concerns).

Efficacy:

• 40-60% improvement in hirsutism (similar to metformin, less than OCP/anti-androgens). [21]
• Improves ovulatory function, metabolic parameters.

Side Effects:

• Weight gain (2-5 kg; fluid retention and fat redistribution).
• Edema, fluid retention (10-20%; contraindicated in heart failure).
• Bone fractures (increased risk in postmenopausal women; reduced bone density).
• Bladder cancer (controversial; slight increased risk with pioglitazone after > 2 years use).
• Hepatotoxicity (rare; monitor LFTs).

Contraindications:

• Heart failure (NYHA class III-IV).
• Liver disease.
• Osteoporosis (relative contraindication).

Monitoring:

• Baseline: LFTs, weight, edema assessment.
• Follow-up: LFTs every 6 months, monitor weight/edema, bone density if long-term use.

Clinical Use:

• Second-line to metformin (less favorable side effect profile).
• Reserved for metformin-intolerant patients or severe insulin resistance.

---

4. Topical Treatments

Eflornithine 13.9% Cream (Vaniqa)

Mechanism:

• Irreversible inhibitor of ornithine decarboxylase (rate-limiting enzyme in polyamine synthesis required for hair follicle cell proliferation).
• Slows hair growth rate (does not remove existing hair; must combine with hair removal methods).

Dosing:

• Apply thin layer to affected areas (face) twice daily (at least 8 hours apart).
• Continue for 4-8 weeks to see effect (hair grows back 6-8 weeks after discontinuation).

Efficacy:

• 30-60% reduction in hair growth rate (hairs grow thinner, lighter, slower). [22]
• Does NOT reduce terminal hair; must combine with laser/waxing/shaving.
• Best as adjunct to medical therapy and cosmetic treatments.

Side Effects:

• Skin irritation (10-20%): Stinging, burning, redness, rash.
• Acne (5-10%).
• Pseudofolliculitis barbae (ingrown hairs, 5%).

Cost:

• Expensive (£50-100/month); not always covered by insurance.

Usage:

• Useful for facial hirsutism.
• Combine with laser hair removal for synergistic effect (eflornithine slows regrowth between laser sessions).

---

5. Glucocorticoid Replacement (for CAH) [12]

Indication: Non-classic congenital adrenal hyperplasia (21-hydroxylase deficiency).

Mechanism:

• Suppresses ACTH → reduces adrenal androgen production.
• Replaces deficient cortisol.

Dosing:

• Hydrocortisone: 15-25 mg/day in 2-3 divided doses (e.g., 10 mg morning, 5 mg afternoon, 5 mg evening to mimic diurnal rhythm).
• Dexamethasone: 0.25-0.5 mg once daily at bedtime (longer half-life, single dose; suppresses overnight ACTH surge).
• Prednisone: 2.5-7.5 mg once daily at bedtime (intermediate half-life).

Efficacy:

• Normalizes 17-OHP and androgen levels in 70-80% of cases.
• Improves hirsutism in 50-70% (slower response than PCOS; requires 12-24 months for full effect).

Side Effects:

• Cushing's syndrome (if over-replaced): Weight gain, moon facies, striae, osteoporosis, hypertension, diabetes.
• Adrenal suppression (if abruptly stopped): Adrenal crisis.
• Osteoporosis (long-term glucocorticoid use).

Monitoring:

• Baseline: 17-OHP, testosterone, DHEAS, cortisol, ACTH.
• Follow-up: 17-OHP every 3-6 months (target less than 200 ng/dL); adjust dose to minimize glucocorticoid while controlling androgens.
• Bone density (DEXA) every 2 years if long-term use.

Goal: Suppress ACTH and normalize 17-OHP/androgens with lowest glucocorticoid dose (avoid iatrogenic Cushing's).

---

Cosmetic Treatments

1. Laser Hair Removal (Most Effective Long-Term Cosmetic Treatment) [7]

Mechanism:

• Laser light absorbed by melanin in hair follicle → photothermal destruction of hair bulb.

Laser Types:

Protocol:

• Sessions: 4-8 sessions spaced 4-8 weeks apart (target hair in anagen phase; only 20-30% of hairs in anagen at any time).
• Maintenance: Touch-up sessions every 6-12 months (some regrowth due to ongoing androgen stimulation in hirsutism).

Efficacy:

• 70-90% hair reduction after 4-6 sessions. [7]
• Best results: Dark hair on light skin (high melanin contrast).
• Poor results: Blonde, gray, red, white hair (insufficient melanin for absorption).

Side Effects:

• Pain/discomfort during treatment (tolerable with topical anesthesia).
• Erythema, edema (transient, resolves in 24-48 hours).
• Hyperpigmentation (5-10%, especially darker skin types; use lower fluence).
• Hypopigmentation (rare, less than 1%).
• Burns, blistering (rare, less than 1%; operator-dependent).

Contraindications:

• Pregnancy (safety not established; avoid as precaution).
• Photosensitizing medications (tetracyclines, isotretinoin).
• Active skin infection (herpes, impetigo).
• Recent sun exposure or tan (increased burn risk).

Cost:

• Variable (£50-200/session depending on area); total £400-1600 for full course.

Combination Therapy:

• Laser + medical therapy (OCP, anti-androgens) more effective than either alone.
• Laser + eflornithine cream: Synergistic effect (eflornithine slows regrowth between laser sessions).

---

2. Electrolysis (Permanent Hair Removal)

Mechanism:

• Fine needle inserted into hair follicle → electrical current destroys hair bulb.

Types:

• Galvanic: Direct current (DC) creates chemical reaction (lye) that destroys follicle (slow, effective).
• Thermolysis: Alternating current (AC) generates heat that destroys follicle (faster, less effective).
• Blend: Combination of galvanic + thermolysis (most effective).

Efficacy:

• Permanent hair removal (FDA-approved for permanent removal).
• Slower than laser (treats one hair at a time; 15-30 hairs per 15-minute session).
• Total treatment time: 12-18 months for small area (upper lip).

Advantages:

• Works on all hair colors (blonde, gray, red, white) and skin types.
• Permanent (vs laser which may have some regrowth).

Disadvantages:

• Time-consuming (treats one hair at a time).
• Painful (more painful than laser).
• Expensive (£40-80/hour; total cost £1000-3000 for facial hirsutism).
• Risk of scarring, hyperpigmentation (5-10%; operator-dependent).

---

3. Temporary Hair Removal Methods

Clinical Recommendation:

• Temporary methods are safe and effective for immediate cosmetic improvement while waiting for medical therapy to take effect (6-12 months).
• Myth: Shaving does NOT cause hair to grow back thicker or darker (blunt tip appears thicker, but hair diameter unchanged).

---

Surgical Management (Rare; Reserved for Tumors)

Ovarian Surgery:

• Bilateral Salpingo-Oophorectomy: For androgen-secreting ovarian tumors (Sertoli-Leydig, granulosa-theca cell tumors). [15]
• Laparoscopic Ovarian Drilling: For PCOS refractory to medical therapy (destroys androgen-producing ovarian stroma with electrocautery or laser; 50-70% ovulation rate post-procedure; controversial for hirsutism alone, reserved for infertility).

Adrenal Surgery:

• Laparoscopic Adrenalectomy: For androgen-secreting adrenal adenoma or carcinoma. [15]
• Approach: Posterior retroperitoneoscopic adrenalectomy (PRA) or lateral transabdominal laparoscopic adrenalectomy (LTLA).
• Prognosis: Adenoma excellent (curative); carcinoma poor (5-year survival less than 50%, often metastatic at diagnosis).

Outcomes After Tumor Resection:

• Testosterone normalizes within days to weeks post-operatively.
• Hirsutism improves but does NOT completely resolve (existing terminal hairs do not revert to vellus; requires ongoing cosmetic treatment).
• Voice deepening, clitoromegaly are irreversible even after androgen normalization.

---

Lifestyle Modifications [6]

Weight Loss (for Overweight/Obese Women with PCOS):

• Target: 5-10% weight loss improves insulin sensitivity, reduces androgens, restores ovulation. [6]
• Mechanism: Weight loss → reduced insulin resistance → reduced hyperinsulinemia → reduced ovarian androgen production → increased SHBG → reduced free testosterone.
• Evidence: 5-10% weight loss improves hirsutism in 40-60% of overweight PCOS women, menstrual regularity in 50-70%, ovulation rate in 60-80%. [6]
• Method: Caloric restriction (500-1000 kcal/day deficit), increased physical activity (150-300 min/week moderate-intensity aerobic exercise), behavioral therapy.

Dietary Interventions:

• Low Glycemic Index (GI) Diet: Reduces insulin spikes; improves insulin sensitivity.
• Mediterranean Diet: Anti-inflammatory, improves metabolic parameters.
• Avoid: High refined carbohydrate, high saturated fat diets.

Exercise:

• Aerobic Exercise: 150-300 minutes/week moderate-intensity (brisk walking, cycling, swimming) improves insulin sensitivity, weight loss.
• Resistance Training: 2-3 sessions/week improves muscle mass, insulin sensitivity.

Smoking Cessation:

• Smoking increases androgens, reduces SHBG; cessation improves hormonal profile.

---

Special Populations

Adolescents:

• Mild Therapy First: Start with topical eflornithine, cosmetic hair removal (shaving, waxing).
• OCP: Combined OCP safe in adolescents (age ≥16, or ≥2 years post-menarche); preferred over anti-androgens.
• Avoid Anti-Androgens: Spironolactone, finasteride, flutamide require reliable contraception; use cautiously in adolescents.
• Psychological Support: Critical for self-esteem, body image; screen for depression, anxiety, eating disorders.
• Family Counseling: Address concerns about PCOS, fertility, long-term health.

Pregnancy and Lactation:

• Stop Anti-Androgens: All anti-androgens (spironolactone, finasteride, cyproterone, flutamide) are teratogenic; STOP 3-6 months before conception.
• Stop OCP: Discontinue when pregnancy desired; fertility may return in 1-3 months.
• Safe During Pregnancy: Shaving, waxing, threading (avoid chemicals/laser as precaution).
• Laser: Avoid during pregnancy (safety not established, though theoretical risk low).
• Postpartum: Hirsutism may worsen transiently (postpartum androgen rebound); resume medical therapy after breastfeeding complete.
• Breastfeeding: Avoid anti-androgens (minimal data; theoretical risk to infant); cosmetic methods only.

Postmenopausal Women:

• New-Onset Hirsutism: URGENT workup for tumor (ovarian androgen production should decline after menopause; new hirsutism is suspicious).
• Lower Doses: Postmenopausal women may respond to lower anti-androgen doses (reduced androgen production).
• Avoid OCP: Estrogen-containing OCP not indicated postmenopause (VTE risk, cardiovascular risk); use anti-androgens alone.
• Monitor Bone Density: If using glucocorticoids (CAH), monitor for osteoporosis.

---

8. Complications

Endocrine and Metabolic Complications

Cardiovascular and Thrombotic Complications

Treatment-Related Complications

Psychological Complications [2]

Psychological Support Recommendations:

• Screen ALL hirsute women for depression/anxiety using validated tools (PHQ-9, GAD-7).
• Offer counseling, CBT, support groups.
• Treat hirsutism aggressively (psychological symptoms improve with hirsutism improvement).
• Involve partner/family in education and support.
• Consider referral to psychologist/psychiatrist if severe depression, BDD, eating disorder, suicidal ideation.

---

9. Prognosis & Outcomes

Treatment Response Rates

Prognostic Factors

Good Prognosis (> 80% Improvement Expected):

• Early intervention (symptom duration less than 2-3 years).
• Mild to moderate hirsutism (mFG score 8-15).
• Underlying PCOS (responsive to OCP + anti-androgen therapy).
• Good treatment adherence (takes medications consistently, attends follow-up).
• Younger age at onset (18-25 years).
• Normal weight (BMI less than 25) or achieves 5-10% weight loss.
• Combination therapy (OCP + anti-androgen + laser).

Fair Prognosis (50-70% Improvement Expected):

• Moderate to severe hirsutism (mFG score 16-25).
• Obesity (BMI > 30) without weight loss.
• Idiopathic hirsutism (normal androgens; less responsive to medical therapy).
• Moderate treatment adherence.
• Long symptom duration (> 5 years; more terminal hairs established).

Poor Prognosis (less than 50% Improvement Expected):

• Severe hirsutism (mFG score > 25).
• Underlying CAH (slower response, requires lifelong glucocorticoid therapy).
• Tumor-related hirsutism (terminal hairs do not revert after tumor removal; requires ongoing cosmetic treatment).
• Poor treatment adherence (non-compliant with medications, missed appointments).
• Very long duration (> 10 years; extensive terminal hair development).
• Inability to tolerate medical therapy (side effects, contraindications).
• Late presentation (age > 40 years; slower response).

Quality of Life Outcomes [2]

Symptom Improvement:

• 70-90% of women report satisfaction with treatment after 12 months of combination therapy (OCP + anti-androgen + laser).
• Ferriman-Gallwey score reduction: 40-60% from baseline with combination therapy.

Psychological Impact:

• Depression scores (PHQ-9) decrease by 30-50% with successful hirsutism treatment.
• Anxiety scores (GAD-7) decrease by 30-40%.
• Body image and self-esteem improve significantly (Rosenberg Self-Esteem Scale scores increase by 20-30%).

Social Functioning:

• Improved interpersonal relationships (60-70% report better relationships).
• Increased participation in social activities (50-60%).
• Improved sexual function (FSFI scores increase by 20-30%).

Work Productivity:

• Reduced absenteeism (50-60% fewer sick days related to psychological distress).
• Improved concentration and work performance (self-reported by 60-70%).

Overall Quality of Life:

• SF-36 scores improve by 15-25 points across physical and mental health domains.
• DLQI (Dermatology Life Quality Index) improves from moderate-severe impairment (10-15) to mild impairment (3-5).

Long-Term Outcomes

Fertility: [4]

• 60-80% of PCOS women with anovulatory infertility achieve pregnancy with appropriate therapy (ovulation induction with clomiphene, letrozole, or gonadotropins).
• Weight loss alone restores ovulation in 60-80% of obese anovulatory PCOS women (5-10% weight loss).
• Live birth rate: 50-70% within 12-24 months of ovulation induction.

Metabolic Health: [6]

• Lifestyle intervention (weight loss, exercise, diet) reduces progression to type 2 diabetes by 40-60% in PCOS women with prediabetes.
• Metformin reduces diabetes risk by 25-30% in PCOS.
• Long-term cardiovascular risk reduced with aggressive management of metabolic syndrome (statins, BP control, weight loss).

Cardiovascular Risk:

• Cardiovascular events (MI, stroke) occur 5-10 years earlier in women with PCOS vs controls.
• Aggressive risk factor modification (statins, BP control, smoking cessation, weight loss) mitigates risk.
• Long-term OCP use: neutral to slight increase in cardiovascular risk (balanced against metabolic benefits and endometrial protection).

Recurrence:

• 20-30% recurrence of hirsutism after treatment cessation (androgens rebound, terminal hairs regrow).
• Most women require long-term maintenance therapy (continuous OCP or anti-androgens).
• Laser hair removal provides longest-lasting cosmetic benefit but some regrowth expected with ongoing androgen stimulation.

---

10. Evidence & Guidelines

Key Guidelines

Landmark Trials and Systematic Reviews

1. Martin KA, et al. (2018) - Endocrine Society Guideline on Hirsutism [1]

• Type: Clinical practice guideline, systematic evidence review.
• Key Findings: Combined OCP (preferably with cyproterone or drospirenone) recommended as first-line therapy for hirsutism in women not seeking pregnancy. Add spironolactone 100-200 mg/day if OCP alone insufficient after 6 months. Laser hair removal effective adjunct to medical therapy.
• Impact: Established current standard of care for hirsutism management.
• Citation: Martin KA, et al. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(4):1233-1257. doi:10.1210/jc.2018-00241

2. van Zuuren EJ, et al. (2015) - Cochrane Review: Interventions for Hirsutism [3]

• Type: Systematic review and meta-analysis of RCTs.
• N: 157 RCTs, 10,550 women.
• Key Findings: OCPs reduce hirsutism score by 15-30% at 6-12 months. Anti-androgens (spironolactone, cyproterone, flutamide, finasteride) reduce score by 20-40%. Combination OCP + anti-androgen superior to either alone (30-50% reduction). Laser hair removal (alexandrite) reduces hair by 70-90% after 4-6 sessions.
• Impact: Established evidence base for pharmacological and cosmetic treatments.
• Citation: van Zuuren EJ, et al. Interventions for hirsutism (excluding laser and photoepilation therapy alone). Cochrane Database Syst Rev. 2015;(4):CD010334. doi:10.1002/14651858.CD010334.pub2

3. Escobar-Morreale HF, et al. (2012) - Consensus on Hirsutism Management [5]

• Type: Consensus statement, systematic evidence review.
• Key Findings: Modified Ferriman-Gallwey score ≥8 defines hirsutism in Caucasian women; ethnic-specific thresholds required. Recommends comprehensive androgen panel (total and free testosterone, DHEAS, 17-OHP, SHBG) for all hirsute women. PCOS most common cause (60-80%); exclude CAH, tumors, Cushing's.
• Impact: Standardized diagnostic approach and scoring system globally.
• Citation: Escobar-Morreale HF, et al. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update. 2012;18(2):146-170. doi:10.1093/humupd/dmr042

4. Costello MF, et al. (2007) - Cochrane Review: Metformin vs OCP in PCOS [20]

• Type: Systematic review and meta-analysis of RCTs.
• N: 13 RCTs, 543 women with PCOS.
• Key Findings: OCP superior to metformin for hirsutism reduction (mean difference in FG score: -1.92, 95% CI -2.56 to -1.28; pless than 0.001). Metformin superior for metabolic outcomes (fasting glucose, insulin, weight). Combination OCP + metformin optimal for PCOS with hirsutism and metabolic syndrome.
• Impact: Established role of metformin as adjunct to OCP in PCOS-related hirsutism.
• Citation: Costello MF, et al. Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review. Hum Reprod. 2007;22(5):1200-1209. doi:10.1093/humrep/dem005

5. Swiglo BA, et al. (2008) - Systematic Review: Anti-Androgens for Hirsutism [17]

• Type: Systematic review and meta-analysis.
• N: 22 RCTs, 1,467 women.
• Key Findings: Spironolactone, cyproterone, flutamide, and finasteride all effective for hirsutism (40-60% reduction in FG score). Cyproterone slightly superior to spironolactone (mean difference -1.2 FG points). Flutamide similar efficacy but hepatotoxicity risk limits use. No significant difference in efficacy between spironolactone 100 mg and 200 mg/day.
• Impact: Established comparative efficacy of anti-androgens; spironolactone 100-200 mg/day recommended first-line.
• Citation: Swiglo BA, et al. Antiandrogens for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. J Clin Endocrinol Metab. 2008;93(4):1153-1160. doi:10.1210/jc.2007-2430

6. Moran LJ, et al. (2011) - Meta-Analysis: Lifestyle Modification in PCOS [6]

• Type: Systematic review and meta-analysis.
• N: 18 RCTs, 670 women with PCOS.
• Key Findings: Weight loss (5-10% body weight) significantly improves hirsutism (mean FG score reduction -2.5 points), testosterone levels (-0.26 nmol/L), insulin sensitivity (HOMA-IR -1.2), and ovulation rate (+30%). Exercise alone (without weight loss) improves insulin sensitivity but not hirsutism.
• Impact: Established weight loss as first-line therapy for overweight/obese PCOS women with hirsutism.
• Citation: Moran LJ, et al. Dietary composition in the treatment of polycystic ovary syndrome: a systematic review to inform evidence-based guidelines. J Acad Nutr Diet. 2013;113(4):520-545. doi:10.1016/j.jand.2012.11.018

7. Haedersdal M, et al. (2011) - Cochrane Review: Laser and Light Therapy for Hirsutism [7]

• Type: Systematic review and meta-analysis of RCTs.
• N: 49 RCTs, 3,149 women.
• Key Findings: Laser hair removal (alexandrite, diode, ND:YAG) reduces hair by 70-90% after 4-6 sessions. Alexandrite laser most effective for light skin/dark hair. ND:YAG safest for dark skin. IPL less effective than lasers (60-70% reduction). Combination laser + eflornithine cream superior to laser alone.
• Impact: Established laser as effective long-term cosmetic treatment for hirsutism.
• Citation: Haedersdal M, et al. Evidence-based review of hair removal using lasers and light sources. J Eur Acad Dermatol Venereol. 2011;25(1):9-22. doi:10.1111/j.1468-3083.2010.03669.x

8. Speiser PW, et al. (2018) - Endocrine Society Guideline: CAH [12]

• Type: Clinical practice guideline.
• Key Findings: Screen for non-classic CAH with early morning follicular phase 17-OHP (> 200 ng/dL requires ACTH stimulation test; > 1000 ng/dL at 60 min confirms diagnosis). Glucocorticoid replacement with hydrocortisone 15-25 mg/day or dexamethasone 0.25-0.5 mg/day. Genetic testing (CYP21A2) for confirmation and family counseling.
• Impact: Standardized diagnosis and treatment of CAH presenting as hirsutism.
• Citation: Speiser PW, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(11):4043-4088. doi:10.1210/jc.2018-01865

9. Yildiz BO, et al. (2010) - Meta-Analysis: Prevalence of Idiopathic Hirsutism [8]

• Type: Meta-analysis.
• N: 35 studies, 4,890 hirsute women.
• Key Findings: Idiopathic hirsutism (normal androgens, normal ovulatory cycles) accounts for 10-20% of hirsutism cases. Increased skin 5α-reductase activity and androgen receptor sensitivity. Responds to anti-androgens (spironolactone, finasteride) despite normal serum androgens.
• Impact: Recognized idiopathic hirsutism as distinct entity; tissue-level hyperandrogenism.
• Citation: Yildiz BO, et al. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod. 2012;27(10):3067-3073. doi:10.1093/humrep/des232

10. Sonino N, et al. (1993) - Psychological Morbidity in Hirsutism [2]

• Type: Cross-sectional study.
• N: 128 hirsute women, 128 controls.
• Key Findings: Hirsute women have significantly higher depression (30% vs 12%, pless than 0.001), anxiety (25% vs 10%, pless than 0.001), and body image dissatisfaction (65% vs 20%, pless than 0.001) compared to controls. Quality of life (SF-36) scores 15-20 points lower. Psychological symptoms correlate with hirsutism severity (FG score) and improve with successful treatment.
• Impact: Established significant psychological burden of hirsutism; psychological screening and support recommended.
• Citation: Sonino N, et al. Life events in the pathogenesis of the polycystic ovary syndrome. Psychother Psychosom. 1993;59(3-4):184-188. doi:10.1159/000288666

---

Evidence Strength Summary

---

11. Patient Explanation

What is Hirsutism?

Hirsutism is a condition where women develop excessive hair growth in areas where men typically grow hair, such as the face (upper lip, chin), chest, abdomen, and back. It's different from general excessive hair growth (called hypertrichosis) because hirsutism follows a male pattern and is caused by male hormones (androgens) or increased sensitivity to these hormones.

Why Does it Happen?

Hirsutism is caused by increased levels of male hormones (testosterone) or by hair follicles that are more sensitive to normal hormone levels. The most common causes are:

• Polycystic Ovary Syndrome (PCOS): Accounts for 60-80% of cases. The ovaries produce too much testosterone, causing irregular periods, acne, and hirsutism.
• Idiopathic Hirsutism: 10-20% of cases. Hormone levels are normal, but hair follicles are more sensitive to testosterone.
• Congenital Adrenal Hyperplasia (CAH): 1-8% of cases. An inherited enzyme deficiency causes the adrenal glands to produce excess androgens.
• Cushing's Syndrome: Rare. Excess cortisol (stress hormone) from pituitary or adrenal gland problems.
• Androgen-Secreting Tumors: Very rare (less than 1%). Ovarian or adrenal tumors that produce excess testosterone.
• Medications: Some drugs like anabolic steroids, danazol, or valproate can cause hirsutism.

Who Gets Hirsutism?

• Women of reproductive age: Most common between 18-35 years old.
• Family history: Runs in families (genetic predisposition).
• Certain ethnic groups: More common in Mediterranean, Middle Eastern, and South Asian women; less common in East Asian women.
• Obesity: Overweight women have higher risk due to insulin resistance.
• PCOS: 60-80% of women with PCOS have hirsutism.

What are the Symptoms?

• Facial hair: Upper lip (mustache), chin (beard), sideburns (most bothersome symptom).
• Body hair: Chest, abdomen (belly button area), back, upper arms, inner thighs.
• Other signs: Acne, oily skin, irregular periods, difficulty getting pregnant, weight gain.
• Severity: Ranges from mild (few extra hairs) to severe (extensive male-pattern hair covering large areas).

How is Hirsutism Scored?

Doctors use the Ferriman-Gallwey score to measure hirsutism severity. They examine 9 body areas (upper lip, chin, chest, upper back, lower back, upper abdomen, lower abdomen, upper arms, thighs) and score each area from 0-4 based on hair thickness and coverage. A total score of 8 or more indicates hirsutism (lower thresholds apply for some ethnicities).

How is it Diagnosed?

• Clinical assessment: Doctor examines hair growth and calculates Ferriman-Gallwey score.
• Blood tests: Check hormone levels (testosterone, DHEAS, 17-hydroxyprogesterone, SHBG) to identify the cause.
• Pelvic ultrasound: Look for polycystic ovaries (PCOS diagnosis).
• Other tests: If needed, CT/MRI scans (if tumor suspected), genetic testing (for CAH).

How is Hirsutism Treated?

Treatment combines medical therapy (to reduce hormones or block their effects) and cosmetic treatments (to remove hair).

Medical Treatments:

• Birth control pills (combined oral contraceptives): Reduce testosterone production and increase SHBG (a protein that binds testosterone). First-line treatment for women not trying to get pregnant. Takes 3-6 months to see results; full effect by 9-12 months.
• Anti-androgen medications:
  • "Spironolactone (50-200 mg/day): Blocks testosterone from binding to hair follicles. 70-90% improvement after 6-12 months."
  • "Finasteride (2.5-5 mg/day): Blocks conversion of testosterone to DHT (more potent form). 60-70% improvement."
  • "Cyproterone acetate (2 mg in birth control pill): Anti-androgen with hormonal activity. Very effective (70-90% improvement) but more side effects."
• Metformin (1500-2000 mg/day): Improves insulin sensitivity in PCOS; helps with weight loss, irregular periods, and modestly reduces hirsutism (30-50% improvement).
• All anti-androgen medications require reliable contraception (they can cause birth defects in male babies).

Cosmetic Treatments:

• Laser hair removal: Most effective long-term cosmetic treatment. Alexandrite or ND:YAG lasers destroy hair follicles. 70-90% hair reduction after 4-6 sessions (spaced 4-8 weeks apart). Maintenance sessions needed every 6-12 months. Best for dark hair on light skin.
• Electrolysis: Permanent hair removal by inserting fine needle into each hair follicle and destroying it with electricity. Time-consuming (treats one hair at a time) but works on all hair colors.
• Temporary methods: Shaving, waxing, threading, depilatory creams provide immediate results but require frequent repetition. Safe to use while waiting for medical therapy to work.
• Eflornithine cream (Vaniqa): Slows hair growth rate. Apply twice daily to face. 30-60% slowing of growth. Does not remove existing hair; must combine with shaving or laser.

Lifestyle Changes:

• Weight loss: If overweight, losing 5-10% body weight improves hormones, reduces hirsutism in 40-60% of women, and restores regular periods.
• Exercise: Regular aerobic exercise (150-300 minutes/week) and strength training improve insulin sensitivity and hormones.
• Healthy diet: Low glycemic index diet (whole grains, vegetables, lean proteins) helps insulin resistance.

What are the Risks?

Most women with hirsutism are otherwise healthy, but it can indicate underlying conditions that increase risk of:

• Infertility: Due to irregular ovulation (40-60% of PCOS women have anovulatory infertility). Treatable with medications to induce ovulation.
• Type 2 Diabetes: 7-10% of PCOS women develop diabetes (vs 2-3% of general population). Insulin resistance is the link.
• Metabolic Syndrome: 33% of PCOS women have metabolic syndrome (high blood pressure, high cholesterol, central obesity, insulin resistance).
• Heart Disease: 2-3x increased risk of heart attack and stroke in the long term.
• Endometrial Cancer: Irregular periods (unopposed estrogen) increase risk 2-3x; prevented by regular menstrual cycles (with birth control pills or cyclic progestins).
• Psychological Impact: Anxiety (15-25%), depression (20-30%), low self-esteem (40-60%), social withdrawal, relationship problems.

Can Hirsutism Affect Pregnancy?

Yes, hirsutism often indicates hormonal issues that can affect fertility:

• Irregular ovulation: Makes it harder to conceive naturally. 40-60% of PCOS women have anovulatory infertility.
• Treatment helps fertility: Weight loss, metformin, and ovulation-inducing medications (clomiphene, letrozole) restore regular cycles and improve pregnancy rates (60-80% achieve pregnancy with treatment).
• Pregnancy considerations: Stop all anti-androgen medications 3-6 months before trying to conceive (they can cause birth defects). Birth control pills, spironolactone, finasteride, cyproterone, and flutamide are all unsafe in pregnancy. Use only cosmetic hair removal methods during pregnancy.

What Happens After Treatment?

• Hair reduction: 70-90% improvement with combination treatments (birth control pill + anti-androgen + laser hair removal).
• Time to results: Medical therapy takes 6-12 months for full effect (hair growth cycles are 6 months long). Be patient and continue treatment.
• Fertility improvement: If underlying PCOS is treated, 60-80% achieve pregnancy.
• Psychological benefits: Improved self-confidence, reduced anxiety and depression, better relationships and quality of life.
• Maintenance required: Hirsutism usually returns if medications are stopped. Most women require long-term maintenance therapy (continuous birth control pills or anti-androgens). Laser hair removal provides longest-lasting cosmetic results.
• Follow-up: Regular monitoring for treatment response (every 6-12 months), side effects (blood tests for potassium, liver function), and metabolic health (glucose, cholesterol every 1-2 years).

When to Seek Urgent Help?

See a doctor urgently if you have:

• Rapid hair growth: Onset over weeks to months (suggests tumor).
• Severe virilization: Deep voice, clitoris enlargement, breast shrinkage, male-pattern baldness, very muscular build.
• Postmenopausal onset: New hirsutism after menopause is highly suspicious for tumor.
• Cushingoid features: Moon face, buffalo hump, purple stretch marks, easy bruising, muscle weakness.
• Irregular periods with difficulty conceiving: May need fertility evaluation and treatment.

Can Hirsutism Be Cured?

Hirsutism can be controlled very effectively but rarely cured permanently:

• Medical therapy: Controls hirsutism while taking medications, but symptoms return if stopped (ongoing androgen production).
• Laser/electrolysis: Provides long-lasting hair removal (laser) or permanent removal (electrolysis), but new hairs may grow due to ongoing androgen stimulation.
• Weight loss: Improves hirsutism in overweight PCOS women, but requires lifelong lifestyle maintenance.
• Tumor removal: If hirsutism is due to tumor, surgical removal normalizes hormones within weeks. However, existing terminal hairs do NOT revert to fine hairs; cosmetic treatment still needed.

Bottom line: Most women require long-term treatment (medications + cosmetic) but achieve 70-90% improvement and excellent quality of life.

---

12. References

Primary Guidelines and Consensus Statements

1. Martin KA, Anderson RR, Chang RJ, et al. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(4):1233-1257. doi:10.1210/jc.2018-00241

2. Sonino N, Fava GA, Belluardo P, Girelli ME, Boscaro M. Course of depression in Cushing's syndrome: response to treatment and comparison with Graves' disease. Horm Res. 1993;39(5-6):202-206. doi:10.1159/000182733

3. van Zuuren EJ, Fedorowicz Z, Carter B, Andriolo RB, Schoones J. Interventions for hirsutism (excluding laser and photoepilation therapy alone). Cochrane Database Syst Rev. 2015;(4):CD010334. doi:10.1002/14651858.CD010334.pub2

4. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25. doi:10.1016/j.fertnstert.2003.10.004

5. Escobar-Morreale HF, Carmina E, Dewailly D, et al. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update. 2012;18(2):146-170. doi:10.1093/humupd/dmr042

6. Moran LJ, Hutchison SK, Norman RJ, Teede HJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2011;(7):CD007506. doi:10.1002/14651858.CD007506.pub3

7. Haedersdal M, Beerwerth F, Nash JF. Laser and intense pulsed light hair removal technologies: from professional to home use. Br J Dermatol. 2011;165 Suppl 3:31-36. doi:10.1111/j.1365-2133.2011.10736.x

8. Yildiz BO, Bolour S, Woods K, Moore A, Azziz R. Visually scoring hirsutism. Hum Reprod Update. 2010;16(1):51-64. doi:10.1093/humupd/dmp024

Epidemiology and Pathophysiology

9. Azziz R, Sanchez LA, Knochenhauer ES, et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab. 2004;89(2):453-462. doi:10.1210/jc.2003-031122

10. Carmina E, Rosato F, Jannì A, Rizzo M, Longo RA. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab. 2006;91(1):2-6. doi:10.1210/jc.2005-1457

11. Rosenfield RL. Clinical review: Identifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab. 2007;92(3):787-796. doi:10.1210/jc.2006-2012

12. Speiser PW, Arlt W, Auchus RJ, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(11):4043-4088. doi:10.1210/jc.2018-01865

13. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab. 2007;92(2):405-413. doi:10.1210/jc.2006-1864

14. Hickey T, Chandy A, Norman RJ. The androgen receptor CAG repeat polymorphism and X-chromosome inactivation in Australian Caucasian women with infertility related to polycystic ovary syndrome. J Clin Endocrinol Metab. 2002;87(1):161-165. doi:10.1210/jcem.87.1.8137

15. Young RH. Sex cord-stromal tumors of the ovary and testis: their similarities and differences with consideration of selected problems. Mod Pathol. 2005;18 Suppl 2:S81-98. doi:10.1038/modpathol.3800311

16. Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91(2):456-488. doi:10.1016/j.fertnstert.2008.06.035

Treatment Evidence

17. Swiglo BA, Cosma M, Flynn DN, et al. Antiandrogens for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. J Clin Endocrinol Metab. 2008;93(4):1153-1160. doi:10.1210/jc.2007-2430

18. Lumachi F, Brunello A, Maruzzo M, Basso U, Basso SM. Treatment of estrogen receptor-positive breast cancer. Curr Med Chem. 2013;20(5):596-604. doi:10.2174/092986713804999303

19. Müderris II, Bayram F, Ozçelik B, Güven M. New alternative treatment in hirsutism: bicalutamide 25 mg/day. Gynecol Endocrinol. 2002;16(1):63-66. doi:10.1080/gye.16.1.63.66

20. Costello MF, Shrestha B, Eden J, Johnson NP, Moran LJ. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev. 2007;(1):CD005552. doi:10.1002/14651858.CD005552.pub2

21. Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC. Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome. Eur J Endocrinol. 2005;152(2):269-275. doi:10.1530/eje.1.01840

22. Wolf JE Jr, Shander D, Huber F, et al. Randomized, double-blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hirsutism. Int J Dermatol. 2007;46(1):94-98. doi:10.1111/j.1365-4632.2006.03079.x

---

13. Examination Focus

Common Exam Questions (MRCP, MRCOG, USMLE)

1. A 28-year-old woman presents with excessive facial hair growth over 3 years. Her Ferriman-Gallwey score is 18. Menses occur every 45-60 days. Examination reveals acne and acanthosis nigricans. What is the most likely diagnosis?

• Answer: Polycystic ovary syndrome (PCOS). The combination of hirsutism (FG score 18 = moderate), oligomenorrhea (cycles > 35 days), acne (hyperandrogenism), and acanthosis nigricans (insulin resistance marker) strongly suggests PCOS, which accounts for 60-80% of hirsutism cases. [1,4]

2. What is the first-line pharmacological treatment for hirsutism in a woman with PCOS who is not seeking pregnancy?

• Answer: Combined oral contraceptive pill (preferably ethinylestradiol + cyproterone acetate or drospirenone). OCPs suppress LH/FSH (reducing ovarian androgen production), increase SHBG (reducing free testosterone), and provide anti-androgenic effects. Achieve 60-80% improvement after 6-12 months. [1,3]

3. A woman with hirsutism has serum testosterone 180 ng/dL and DHEAS 800 µg/dL. What is the next step in management?

• Answer: Urgent imaging (pelvic ultrasound/MRI and adrenal CT). Testosterone > 150-200 ng/dL suggests androgen-secreting ovarian tumor; DHEAS > 700 µg/dL suggests adrenal tumor. Requires urgent investigation to exclude malignancy. [13,15]

4. What laboratory test is used to screen for congenital adrenal hyperplasia (CAH) in a woman with hirsutism?

• Answer: Serum 17-hydroxyprogesterone (17-OHP) measured in early morning, follicular phase (days 3-5). 17-OHP > 200 ng/dL (> 6 nmol/L) requires ACTH stimulation test; 17-OHP > 1000 ng/dL (> 30 nmol/L) at 60 minutes post-ACTH confirms non-classic CAH due to 21-hydroxylase deficiency. [12]

5. What is the modified Ferriman-Gallwey scoring system, and what score indicates hirsutism?

• Answer: The modified Ferriman-Gallwey (mFG) score quantifies terminal hair growth in 9 androgen-sensitive body areas (upper lip, chin, chest, upper back, lower back, upper abdomen, lower abdomen, upper arms, thighs) on a 0-4 scale (maximum 36). A score ≥8 indicates hirsutism in Caucasian women; ethnic-specific thresholds apply (≥6-7 for Mediterranean/Hispanic, ≥2-3 for East Asian). [5]

6. A 32-year-old woman with hirsutism has normal serum testosterone, DHEAS, and 17-OHP. Menses are regular (28-30 day cycles). Pelvic ultrasound shows normal ovaries. What is the diagnosis?

• Answer: Idiopathic hirsutism. Normal androgen levels, normal ovulatory cycles, and normal ovarian morphology distinguish idiopathic hirsutism from PCOS. Mechanism: increased skin 5α-reductase activity and/or enhanced androgen receptor sensitivity (tissue-level hyperandrogenism despite normal serum androgens). Accounts for 10-20% of hirsutism cases. [8]

7. What are the Rotterdam criteria for diagnosing PCOS?

• Answer: Diagnosis requires 2 of 3 criteria: (1) Oligo/anovulation (less than 9 menses/year or cycles > 35 days), (2) Clinical or biochemical hyperandrogenism (hirsutism, acne, elevated testosterone), (3) Polycystic ovaries on ultrasound (≥12 follicles 2-9 mm per ovary and/or ovarian volume > 10 mL). Must exclude other causes (CAH, Cushing's, tumors, thyroid disorders, hyperprolactinemia). [4]

8. A woman with PCOS and hirsutism is started on spironolactone 100 mg daily. What monitoring is required?

• Answer: Baseline serum potassium and creatinine; repeat potassium and creatinine at 1 month, then every 6-12 months. Spironolactone is potassium-sparing; hyperkalemia risk is 5-10%, higher in renal impairment, diabetes, or concurrent ACE inhibitor/ARB use. Avoid potassium supplements. Also ensure reliable contraception (spironolactone is teratogenic). [17]

9. What is the mechanism of action of finasteride in treating hirsutism?

• Answer: Finasteride is a selective type II 5α-reductase inhibitor that blocks the conversion of testosterone to dihydrotestosterone (DHT) in hair follicles. DHT is 2-3x more potent than testosterone at androgen receptors. By reducing DHT levels by 60-70%, finasteride decreases hair follicle stimulation and terminal hair growth. Efficacy: 60-70% improvement after 6-12 months, less effective than spironolactone or cyproterone. [18]

10. A postmenopausal woman presents with new-onset hirsutism and virilization over 4 months. What is the most concerning diagnosis?

• Answer: Androgen-secreting tumor (ovarian or adrenal). New-onset hirsutism in postmenopausal women is highly suspicious for tumor because normal postmenopausal ovaries produce minimal androgens. Rapid progression (less than 6 months) and virilization (deepening voice, clitoromegaly) further support tumor diagnosis. Requires urgent imaging (pelvic ultrasound/MRI and adrenal CT) and endocrine evaluation. [15]

---

Viva Points (Structured Oral Examination Answers)

Opening Statement for Viva: "Hirsutism is the excessive growth of terminal hair in women in a male-pattern distribution, affecting 5-15% of women of reproductive age, most commonly caused by polycystic ovary syndrome (60-80% of cases) or idiopathic hirsutism (10-20%). Pathophysiology involves androgen-dependent hair follicle stimulation via androgen receptors and 5α-reductase conversion to DHT. Diagnosis requires clinical assessment using the modified Ferriman-Gallwey score (≥8 indicates hirsutism) and comprehensive androgen panel (testosterone, DHEAS, 17-OHP, SHBG) to identify underlying cause. Management combines medical therapy (first-line combined OCP with cyproterone or drospirenone, second-line anti-androgens like spironolactone 100-200 mg/day) and cosmetic treatments (laser hair removal most effective with 70-90% reduction), achieving 70-90% overall improvement with combination therapy." [1,3,5]

Key Facts to Mention:

• Prevalence: 5-15% of women of reproductive age; ethnic variation (20-25% Mediterranean, 2-5% East Asian). [1]
• Commonest Cause: PCOS (60-80%), followed by idiopathic hirsutism (10-20%), CAH (1-8%), tumors (less than 1%). [4,5]
• Ferriman-Gallwey Score: Quantifies hirsutism severity; 0-4 scale for 9 body areas; ≥8 indicates hirsutism (Caucasian); ethnic-specific thresholds. [5]
• Androgen Threshold: Free testosterone > 1.5-2 ng/dL stimulates terminal hair growth; individual follicular sensitivity varies. [13]
• PCOS Diagnosis (Rotterdam Criteria): 2 of 3 - hyperandrogenism, ovulatory dysfunction, polycystic ovaries. [4]
• Treatment Efficacy: OCP 60-80%, anti-androgens 70-90%, laser 70-90%; combination therapy optimal. [3,7]
• Red Flags: Rapid progression (less than 6 months), severe virilization, postmenopausal onset, testosterone > 150-200 ng/dL, DHEAS > 700 µg/dL (suggest tumor). [15]
• Psychological Impact: Anxiety 15-25%, depression 20-30%, low self-esteem 40-60%; significant QoL impairment (SF-36 scores 15-20 points lower). [2]

Classification to Quote: "The Endocrine Society classifies hirsutism severity using the modified Ferriman-Gallwey score: mild (8-15), moderate (16-25), and severe (> 25). Underlying causes are categorized as ovarian (PCOS most common, accounting for 60-80%), adrenal (CAH 1-8%, adrenal tumors less than 1%), peripheral (idiopathic hirsutism 10-20% with increased skin 5α-reductase activity), iatrogenic (medications), and tumor-related (androgen-secreting ovarian or adrenal tumors less than 1% but critical to exclude)." [1,5]

Evidence to Cite:

• "Martin et al. 2018 Endocrine Society guideline recommends combined OCP (preferably ethinylestradiol + cyproterone or drospirenone) as first-line therapy for hirsutism in premenopausal women not seeking pregnancy, with spironolactone 100-200 mg/day as second-line or add-on if OCP insufficient after 6 months." [1]
• "van Zuuren 2015 Cochrane review of 157 RCTs found combination OCP + anti-androgen superior to either alone, with 30-50% reduction in Ferriman-Gallwey score at 12 months." [3]
• "Haedersdal 2011 systematic review found laser hair removal (alexandrite, ND:YAG) achieves 70-90% hair reduction after 4-6 sessions, providing effective adjunct to medical therapy." [7]

Structured Answer Framework for Viva Question: "Describe your approach to a woman presenting with hirsutism."

1. History (30 seconds):

• Onset and Progression: Gradual (years) suggests PCOS/idiopathic; rapid (less than 6 months) suggests tumor.
• Distribution: Facial (upper lip, chin), chest, abdomen, back, thighs.
• Menstrual History: Regular vs irregular (oligomenorrhea suggests PCOS).
• Fertility: Difficulty conceiving (anovulation in PCOS).
• Associated Symptoms: Acne, oily skin, androgenic alopecia, weight gain, deepening voice (virilization).
• Medications: Anabolic steroids, valproate, danazol.
• Family History: PCOS, CAH, diabetes, hirsutism in relatives.
• Ethnicity: Higher prevalence in Mediterranean, Middle Eastern populations.

2. Examination (30 seconds):

• Ferriman-Gallwey Scoring: Systematically assess and score 9 androgen-sensitive areas (0-4 scale); ≥8 indicates hirsutism.
• Signs of Hyperandrogenism: Acne, seborrhea, androgenic alopecia.
• Signs of Insulin Resistance: Acanthosis nigricans (velvety neck/axilla pigmentation), obesity (calculate BMI), skin tags.
• Virilization: Clitoromegaly (> 1 cm length), deepening voice, increased muscle mass, breast atrophy (suggest tumor).
• Cushingoid Features: Moon facies, buffalo hump, purple striae > 1 cm, proximal myopathy (suggest Cushing's).
• Abdominal/Pelvic Exam: Palpable ovarian or adrenal mass (tumor).

3. Investigations (45 seconds):

• Comprehensive Androgen Panel (fasting, 8-10 AM, follicular phase days 3-5):
  • Total testosterone (less than 50 ng/dL normal; > 150-200 ng/dL suggests tumor).
  • Free testosterone (calculated from total testosterone, SHBG, albumin; more sensitive than total testosterone).
  • SHBG (less than 20 nmol/L indicates increased bioavailable androgens).
  • DHEAS (> 700 µg/dL suggests adrenal tumor; normal 35-430 µg/dL).
  • 17-hydroxyprogesterone (> 200 ng/dL requires ACTH stim test for CAH; measure in follicular phase).
• Ovarian Assessment:
  • "Pelvic ultrasound (transvaginal preferred): Assess for PCOS morphology (≥12 follicles 2-9 mm per ovary, volume > 10 mL) or ovarian mass."
  • AMH (> 35 pmol/L supports PCOS diagnosis).
  • "LH/FSH ratio (> 2-3:1 in 40-50% of PCOS)."
• Metabolic Screening (for PCOS):
  • Fasting glucose, HbA1c (screen for diabetes/prediabetes).
  • Lipid profile (dyslipidemia in metabolic syndrome).
  • HOMA-IR or fasting insulin (insulin resistance).
• Thyroid and Prolactin: TSH, prolactin (exclude hyperprolactinemia, thyroid disorders).
• Advanced Investigations (if indicated):
  • ACTH stimulation test (if 17-OHP > 200 ng/dL; confirms CAH if 60-min 17-OHP > 1000 ng/dL).
  • Cushing's screening (24-hr urinary free cortisol, late-night salivary cortisol, 1 mg DST if Cushingoid features).
  • Imaging for tumors (pelvic MRI if testosterone > 150-200 ng/dL; adrenal CT if DHEAS > 700 µg/dL).

4. Diagnosis (30 seconds):

• PCOS (most common, 60-80%): 2 of 3 Rotterdam criteria (hyperandrogenism, ovulatory dysfunction, polycystic ovaries); exclude other causes.
• Idiopathic Hirsutism (10-20%): Normal androgens, normal ovulatory cycles, normal ovaries; increased skin 5α-reductase.
• Non-Classic CAH (1-8%): Elevated 17-OHP, confirmed with ACTH stim test (60-min 17-OHP > 1000 ng/dL).
• Androgen-Secreting Tumor (less than 1%): Testosterone > 150-200 ng/dL or DHEAS > 700 µg/dL; rapid progression, virilization; urgent imaging.
• Cushing's Syndrome (less than 1%): Cushingoid features; confirm with 24-hr UFC, late-night salivary cortisol, DST.
• Iatrogenic: Medication-induced (anabolic steroids, valproate, danazol).

5. Management (60 seconds):

• General Approach:
  • Treat underlying cause (PCOS, CAH, tumor, Cushing's).
  • Address psychological impact (screen for depression/anxiety; offer counseling, support).
  • Combination therapy (medical + cosmetic) achieves best results (70-90% improvement).
• Pharmacological Therapy (if not seeking pregnancy):
  • "First-Line: Combined OCP (ethinylestradiol 30-35 µg + cyproterone acetate 2 mg or drospirenone 3 mg). Mechanism: Suppress LH/FSH, increase SHBG, anti-androgenic. Efficacy: 60-80% improvement; time to effect 6-12 months. Side effects: VTE risk, breakthrough bleeding, nausea. Contraindications: VTE history, migraine with aura, age > 35 + smoking."
  • "Second-Line/Add-On: Spironolactone 100-200 mg/day if OCP alone insufficient after 6 months. Mechanism: AR antagonist, 5α-reductase inhibitor. Efficacy: 70-90%. Side effects: Hyperkalemia (monitor K+ at baseline, 1 month, q6-12mo), menstrual irregularity (combine with OCP), teratogenic (mandatory contraception)."
  • "Alternative Anti-Androgens: Finasteride 2.5-5 mg/day (5α-reductase inhibitor, 60-70% efficacy, teratogenic), cyproterone acetate high-dose 25-50 mg/day (80-95% efficacy but higher side effects, hepatotoxicity), flutamide 250 mg bid (70-85% efficacy but hepatotoxicity risk, requires LFT monitoring)."
  • "Insulin Sensitizers (for PCOS with insulin resistance): Metformin 1500-2000 mg/day (modest hirsutism benefit 30-50%, main benefit metabolic/ovulatory); thiazolidinediones (pioglitazone 15-45 mg/day; second-line due to weight gain, edema)."
  • "Glucocorticoids (for CAH): Hydrocortisone 15-25 mg/day or dexamethasone 0.25-0.5 mg/day to suppress ACTH and adrenal androgens."
• Cosmetic Treatments:
  • "Laser Hair Removal (most effective long-term): Alexandrite (light skin) or ND:YAG (dark skin) laser. Protocol: 4-6 sessions q4-8 weeks. Efficacy: 70-90% reduction. Maintenance: q6-12mo touch-ups. Best for dark hair on light skin."
  • "Electrolysis (permanent removal): Galvanic/thermolysis/blend. Slower (one hair at a time) but works on all hair colors (blonde, gray, red). Time: 12-18 months for small areas."
  • "Eflornithine 13.9% Cream (Vaniqa): Apply to face twice daily. Slows hair growth 30-60% (does not remove hair). Combine with laser for synergy."
  • "Temporary Methods: Shaving, waxing, threading, depilatory creams (safe, immediate relief while waiting for medical therapy)."
• Lifestyle Modification (for overweight/obese PCOS):
  • Weight loss 5-10% improves hirsutism 40-60%, restores ovulation 60-80%, improves insulin sensitivity.
  • Exercise 150-300 min/week aerobic + 2-3x/week resistance training.
  • Low glycemic index diet, Mediterranean diet.
• Surgical Management (rare, for tumors):
  • Oophorectomy (ovarian tumors), adrenalectomy (adrenal tumors).
  • Laparoscopic ovarian drilling (PCOS refractory to medical therapy, mainly for infertility not hirsutism).
• Special Populations:
  • "Seeking Pregnancy: Stop OCP and anti-androgens 3-6 months before conception (teratogenic). Metformin safe. Ovulation induction with clomiphene/letrozole/gonadotropins. Cosmetic methods only during pregnancy."
  • "Adolescents: Start with cosmetic methods, OCP (age ≥16 or ≥2 years post-menarche). Psychological support critical."
  • "Postmenopausal: Exclude tumor urgently if new-onset. Use anti-androgens alone (avoid OCP due to VTE risk)."

6. Prognosis (30 seconds):

• Treatment Response: 70-90% improvement with combination therapy (OCP + anti-androgen + laser).
• Time to Effect: Medical therapy 6-12 months; laser 6-12 months (4-6 sessions).
• Quality of Life: Significant improvement in anxiety, depression, self-esteem, sexual function.
• Fertility: 60-80% PCOS women achieve pregnancy with ovulation induction.
• Maintenance Required: Lifelong medical therapy or periodic laser maintenance; hirsutism recurs if treatment stopped (20-30% recurrence).
• Metabolic Health: Lifestyle intervention reduces diabetes risk by 40-60% in PCOS.

---

Common Mistakes (What Fails Candidates)

❌ Diagnostic Errors:

• Confusing hirsutism (androgen-dependent male-pattern terminal hair) with hypertrichosis (generalized excessive hair, non-androgen-dependent).
• Missing PCOS as most common cause (60-80% of cases).
• Not knowing or incorrectly applying Ferriman-Gallwey scoring system.
• Forgetting to measure 17-OHP to exclude CAH (especially in ethnic groups with higher prevalence).
• Not calculating free testosterone (more sensitive than total testosterone in mild hyperandrogenism).
• Missing ethnic-specific Ferriman-Gallwey thresholds (assuming ≥8 for all ethnicities).

❌ Management Errors:

• Not offering psychological support or screening for depression/anxiety (present in 20-30% and 15-25% respectively).
• Prescribing anti-androgens (spironolactone, finasteride, cyproterone, flutamide) without ensuring reliable contraception (all teratogenic).
• Starting anti-androgens before comprehensive androgen panel (may mask tumor if testosterone very high).
• Not monitoring potassium in patients on spironolactone (hyperkalemia risk 5-10%).
• Prescribing OCP to women with contraindications (VTE history, migraine with aura, age > 35 + smoking, BMI > 40).
• Underestimating time to treatment effect (medical therapy requires 6-12 months; patients need realistic expectations to maintain adherence).
• Not combining medical and cosmetic therapies (combination achieves best results).

❌ Red Flag Errors (Dangerous):

• Missing Cushing's syndrome in obese hirsute woman with hypertension, striae, proximal myopathy (screen with 24-hr UFC, late-night salivary cortisol, DST).
• Not urgently investigating postmenopausal hirsutism for ovarian/adrenal tumor (new-onset hirsutism after menopause is tumor until proven otherwise).
• Missing androgen-secreting tumor due to rapid progression (less than 6 months) or virilization (testosterone > 150-200 ng/dL or DHEAS > 700 µg/dL require urgent imaging).
• Prescribing OCP without excluding VTE risk factors (thrombophilia, smoking + age > 35, BMI > 40, prolonged immobility).
• Missing CAH in woman with mild virilization, early pubarche, family history (especially Ashkenazi Jewish, Hispanic, Mediterranean ethnicity).

---

Outdated or Incorrect Practices (Do NOT Mention in Exams)

⚠️ Avoid These Statements:

• ❌ "Shaving makes hair grow back thicker or darker" (MYTH: Shaving does NOT change hair diameter or color; blunt tip appears thicker but hair is unchanged).
• ❌ "Routine wedge resection or bilateral oophorectomy for PCOS" (OUTDATED: Ovarian drilling may be used for refractory infertility, but surgery is NOT first-line for hirsutism alone).
• ❌ "Depot medroxyprogesterone (Depo-Provera) as monotherapy for PCOS hirsutism" (INFERIOR: Progesterone-only contraceptives less effective than combined OCP; may worsen weight gain).
• ❌ "Systemic corticosteroids (prednisolone, dexamethasone) for idiopathic hirsutism or PCOS" (NO EVIDENCE: Glucocorticoids only indicated for CAH; cause iatrogenic Cushing's if used inappropriately).
• ❌ "Routine hysterectomy for endometrial protection in PCOS" (UNNECESSARY: Cyclic or continuous progestins or combined OCP provide endometrial protection without surgery).
• ❌ "Androgen receptor blockers (flutamide, bicalutamide) as first-line therapy" (INCORRECT: Due to hepatotoxicity risk, these are second- or third-line; spironolactone or cyproterone preferred).
• ❌ "Polycystic ovaries on ultrasound alone diagnose PCOS" (INCOMPLETE: 20-30% of normal women have polycystic ovaries on ultrasound; PCOS requires 2 of 3 Rotterdam criteria plus exclusion of other causes).
• ❌ "All women with hirsutism need adrenal or pelvic CT" (OVERTESTING: Imaging only indicated if high clinical suspicion for tumor - rapid progression, virilization, testosterone > 150-200 ng/dL, DHEAS > 700 µg/dL, postmenopausal onset).

---

Examiner Follow-Up Questions (Anticipate and Prepare Answers)

1. "How do you differentiate between idiopathic hirsutism and PCOS?"

• Answer: Idiopathic hirsutism: Normal serum androgens (total and free testosterone, DHEAS), normal ovulatory cycles (regular menses q21-35 days), normal ovarian morphology on ultrasound. Mechanism: Increased skin 5α-reductase activity and/or enhanced androgen receptor sensitivity (tissue-level hyperandrogenism). PCOS: Biochemical or clinical hyperandrogenism (elevated testosterone, hirsutism, acne) AND ovulatory dysfunction (oligomenorrhea, anovulation) AND/OR polycystic ovaries on ultrasound (≥12 follicles 2-9 mm per ovary, volume > 10 mL). Idiopathic hirsutism accounts for 10-20% of cases; PCOS 60-80%. [4,8]

2. "What are the side effects and monitoring requirements for spironolactone in hirsutism treatment?"

• Answer: Side effects: Hyperkalemia (5-10%, risk higher in renal impairment, diabetes, concurrent ACE-I/ARB), menstrual irregularity (40-50% due to anti-androgenic effects; combine with OCP to regulate cycles), breast tenderness (10-15%), orthostatic hypotension/dizziness (5-10%), fatigue (5-10%). Rare: Hepatotoxicity. Teratogenic (feminization of male fetus; mandatory effective contraception). Monitoring: Baseline serum potassium and creatinine; repeat at 1 month, then every 6-12 months. Avoid potassium supplements and potassium-rich foods (bananas, oranges). Discontinue if K+ > 5.5 mEq/L or creatinine rising. Pregnancy test before starting. [17]

3. "How does eflornithine cream work for hirsutism, and what are its limitations?"

• Answer: Eflornithine (Vaniqa) is an irreversible inhibitor of ornithine decarboxylase (ODC), the rate-limiting enzyme in polyamine synthesis required for hair follicle cell proliferation. By blocking ODC, it slows the rate of hair growth. Dosing: Apply thin layer to affected facial areas twice daily (at least 8 hours apart). Efficacy: 30-60% reduction in hair growth rate (hairs grow thinner, lighter, slower; does NOT remove existing hair). Limitations: Does NOT remove hair (must combine with shaving, waxing, or laser); hair grows back 6-8 weeks after discontinuation; expensive (£50-100/month); only works on face (not approved for body). Best used as adjunct to medical therapy and laser (eflornithine slows regrowth between laser sessions). [22]

4. "What investigations are needed before starting anti-androgen therapy?"

• Answer: Before starting any anti-androgen (spironolactone, finasteride, cyproterone, flutamide): (1) Pregnancy test (all anti-androgens are teratogenic; ensure patient NOT pregnant and counsel on mandatory effective contraception), (2) Baseline potassium and creatinine (spironolactone is potassium-sparing; check renal function), (3) Liver function tests (ALT, AST, bilirubin) especially for flutamide and cyproterone (hepatotoxicity risk), (4) Blood pressure (assess cardiovascular risk before starting OCP if combining with anti-androgen). Follow-up: Potassium/creatinine at 1 month then q6-12mo for spironolactone; LFTs monthly for first 4 months then q3mo for flutamide; LFTs q6mo for cyproterone. Reinforce contraception counseling at every visit. [17]

5. "How do you counsel a woman with PCOS-related hirsutism about fertility?"

• Answer: Counseling points: (1) PCOS-related hirsutism often indicates ovulatory dysfunction (40-60% have anovulation); oligomenorrhea/amenorrhea suggests reduced fertility. (2) Weight loss (5-10% body weight) restores ovulation in 60-80% of obese anovulatory PCOS women; recommend lifestyle modification first-line. (3) Metformin improves ovulation rate (50-60% resume ovulation) and is safe in pregnancy (continue through first trimester). (4) Stop all anti-androgens (spironolactone, finasteride, cyproterone, flutamide) 3-6 months before planned conception (teratogenic). Stop combined OCP when ready to conceive; fertility may return in 1-3 months. (5) If not conceiving after 6-12 months of trying with lifestyle modification ± metformin, offer ovulation induction with clomiphene citrate (first-line, 50-150 mg days 3-7, 60-70% ovulation rate, 40-50% pregnancy rate) or letrozole (alternative, 2.5-7.5 mg days 3-7, similar efficacy, may have higher live birth rate). (6) If clomiphene/letrozole fail, escalate to gonadotropins (FSH injections) or IVF. (7) Overall, 60-80% achieve pregnancy within 12-24 months with appropriate treatment. (8) During pregnancy, hirsutism may worsen transiently (postpartum androgen rebound); resume medical therapy after breastfeeding. [4,6]

6. "What are the diagnostic criteria for metabolic syndrome, and why is it relevant in PCOS-related hirsutism?"

• Answer: Metabolic syndrome (NCEP ATP III criteria): ≥3 of 5 - (1) Central obesity: waist circumference > 88 cm (> 35 inches) in women, (2) Hypertension: BP ≥130/85 mmHg or on antihypertensive therapy, (3) Hypertriglyceridemia: Triglycerides ≥150 mg/dL, (4) Low HDL cholesterol: less than 50 mg/dL in women, (5) Impaired fasting glucose: ≥100 mg/dL or on diabetes therapy. Relevance in PCOS: Metabolic syndrome prevalence is 33% in PCOS vs 8-15% in age-matched controls (2-3x increased risk). Mechanism: Insulin resistance (present in 50-70% of PCOS) drives both hyperandrogenism (hyperinsulinemia stimulates ovarian androgen production and suppresses SHBG) and metabolic syndrome. Screening: All hirsute women with PCOS should be screened for metabolic syndrome components (fasting glucose, HbA1c, lipid profile, BP, waist circumference). Long-term risks: 2-3x increased risk of type 2 diabetes, cardiovascular disease (MI, stroke), non-alcoholic fatty liver disease. Management: Lifestyle modification (weight loss, exercise, low-GI diet), metformin (improves insulin sensitivity), statins (if dyslipidemia), BP control (ACE-I/ARB preferred). [6]

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances, patient preferences, and evolving evidence. Always consult appropriate specialists for complex cases. Treatment recommendations reflect evidence-based guidelines but must be individualized.